 <rss version="2.0" 	xmlns:content="http://purl.org/rss/1.0/modules/content/" 	xmlns:wfw="http://wellformedweb.org/CommentAPI/" 	xmlns:dc="http://purl.org/dc/elements/1.1/" 	xmlns:atom="http://www.w3.org/2005/Atom" 	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/" 	xmlns:slash="http://purl.org/rss/1.0/modules/slash/">  	<channel><title><![CDATA[Latest News]]></title><atom:link href="http://www.salisonline.org/news.xml" rel="self" type="application/rss+xml" /> 	<link>http://www.salisonline.org</link> 	<description><![CDATA[Latest News]]></description> 	<lastBuildDate>Wed, 18 Jul 2012 12:20:54 +0000</lastBuildDate> 	<language>en</language> 	<sy:updatePeriod>hourly</sy:updatePeriod> 	<sy:updateFrequency>1</sy:updateFrequency> 	<generator>http://wordpress.org/?v=3.3.1</generator><item><title>Online Laboratory Website Testdiagnostics Expose Alarming Chlamydia Results</title><link>http://www.salisonline.org/news/online-laboratory-website-testdiagnostics-expose-alarming-chlamydia-results.asp</link><comments>http://www.salisonline.org/news/online-laboratory-website-testdiagnostics-expose-alarming-chlamydia-results.asp#comments</comments><pubDate>Wed, 31 Dec 1969 18:00:00 -0600</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.salisonline.org/news/online-laboratory-website-testdiagnostics-expose-alarming-chlamydia-results.asp</guid><description><![CDATA[
London &ndash; UK &nbsp;&mdash; 06/02/2013 &ndash; A recent study released from TestDiagnostics.com has revealed that 16% of adults under the age of 25 have tested positive for Chlamydia. The study took into account 1000 randomly selected tests completed between March 2012 and December 2012.
&nbsp;
The study released by TestDiagnostics.com confirmed that large portions of young adults aged between 18-25 are failing in the practice of safe sex.&nbsp; The percentage of positive test results reduced drastically to 8% for adults over the age of 25.
Visit:&nbsp;http://www.testdiagnostics.com/uk/product/chlamydia-test
Chlamydia has become the most common bacterial STI within the UK and last year over 180,000 new cases were reported.&nbsp; While only 20% of chlamydia cases show symptoms many adults can go undiagnosed for a number of years, which can lead to long term health risks.
If chlamydia is not treated within women it can spread to the uterus, ovaries and fallopian tubes. Women can also develop infections in the Bartholin&rsquo;s gland. This can lead to infertility, increased risk of ectopic pregnancy and miscarriage.
Men can also develop a number of health complications if chlamydia is not diagnosed and treated. These include urethritis, epididymitis and reactive arthritis.&nbsp; The most common of these is urethritis, which happens with the uretha (urine tubed). Symptoms of this would include pain when urinating, urge to urinate frequently and a discharge from the end of the penis.
It is always recommended that if you have had unprotected sex you should have a chlamydia test or a full STI test to ensure you have not been infected. You can easily be tested at your local STI center or alternatively you can purchase a test kit from websites such as TestDiagnostics.com.
While this study outlines an alarming movement within the UK&rsquo;s younger adult population it also reinforces the urgent work that is required in relation to safe sex education. Government health agencies will hope that recent awareness campaigns will curve the alarming trend. To find out more information on the tests available please visit www.testdiagnostics.com/uk
About US
TestDiagnostics.com is a London based testing company specialising in both STI and genetic health. While lab based tests have been around for decades they have largely only been available via the NHS or private clinics. TestDiagnostics.com have pioneered lab based mail order tests, which allows the patient to take the test in the privacy of their own home while also receiving their test results via phone or email.
Test Diagnostics Limited78 York StreetLondonUnited KingdomW1H 1DPPh: 020 3286 2268http://www.testdiagnostics.com/uk/
This Press Release (http://www.culrav.org/pr/online-laboratory-website-testdiagnostics-com-expose-alarming-chlamydia-results.php) Distributed By CULRAV.ORG (http://www.culrav.org/)
 <br><br>Original Post <a href=http://www.salisonline.org/news/online-laboratory-website-testdiagnostics-expose-alarming-chlamydia-results.asp>Online Laboratory Website Testdiagnostics Expose Alarming Chlamydia Results</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></description><content:encoded><![CDATA[
London &ndash; UK &nbsp;&mdash; 06/02/2013 &ndash; A recent study released from TestDiagnostics.com has revealed that 16% of adults under the age of 25 have tested positive for Chlamydia. The study took into account 1000 randomly selected tests completed between March 2012 and December 2012.
&nbsp;
The study released by TestDiagnostics.com confirmed that large portions of young adults aged between 18-25 are failing in the practice of safe sex.&nbsp; The percentage of positive test results reduced drastically to 8% for adults over the age of 25.
Visit:&nbsp;http://www.testdiagnostics.com/uk/product/chlamydia-test
Chlamydia has become the most common bacterial STI within the UK and last year over 180,000 new cases were reported.&nbsp; While only 20% of chlamydia cases show symptoms many adults can go undiagnosed for a number of years, which can lead to long term health risks.
If chlamydia is not treated within women it can spread to the uterus, ovaries and fallopian tubes. Women can also develop infections in the Bartholin&rsquo;s gland. This can lead to infertility, increased risk of ectopic pregnancy and miscarriage.
Men can also develop a number of health complications if chlamydia is not diagnosed and treated. These include urethritis, epididymitis and reactive arthritis.&nbsp; The most common of these is urethritis, which happens with the uretha (urine tubed). Symptoms of this would include pain when urinating, urge to urinate frequently and a discharge from the end of the penis.
It is always recommended that if you have had unprotected sex you should have a chlamydia test or a full STI test to ensure you have not been infected. You can easily be tested at your local STI center or alternatively you can purchase a test kit from websites such as TestDiagnostics.com.
While this study outlines an alarming movement within the UK&rsquo;s younger adult population it also reinforces the urgent work that is required in relation to safe sex education. Government health agencies will hope that recent awareness campaigns will curve the alarming trend. To find out more information on the tests available please visit www.testdiagnostics.com/uk
About US
TestDiagnostics.com is a London based testing company specialising in both STI and genetic health. While lab based tests have been around for decades they have largely only been available via the NHS or private clinics. TestDiagnostics.com have pioneered lab based mail order tests, which allows the patient to take the test in the privacy of their own home while also receiving their test results via phone or email.
Test Diagnostics Limited78 York StreetLondonUnited KingdomW1H 1DPPh: 020 3286 2268http://www.testdiagnostics.com/uk/
This Press Release (http://www.culrav.org/pr/online-laboratory-website-testdiagnostics-com-expose-alarming-chlamydia-results.php) Distributed By CULRAV.ORG (http://www.culrav.org/)
 <br><br>Original Post <a href=http://www.salisonline.org/news/online-laboratory-website-testdiagnostics-expose-alarming-chlamydia-results.asp>Online Laboratory Website Testdiagnostics Expose Alarming Chlamydia Results</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></content:encoded><wfw:commentRss>http://www.salisonline.org/news/online-laboratory-website-testdiagnostics-expose-alarming-chlamydia-results.asp/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Corporate Reputation Management</title><link>http://www.salisonline.org/news/corporate-reputation-management.asp</link><comments>http://www.salisonline.org/news/corporate-reputation-management.asp#comments</comments><pubDate>Wed, 31 Dec 1969 18:00:00 -0600</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.salisonline.org/news/corporate-reputation-management.asp</guid><description><![CDATA[Reputation management is the practice of determining or influencing the behavior of any business or individual&rsquo;s reputation. Originally considered as a public relation term, it was later viewed as an issue of the search results due to the advancements in computing, social media and internet. It deals with the major areas such as astroturfing review sites, use of gamey SEO tactics for influencing results, and censoring negative complaints. It also includes other forms of management such as making use of online feedbacks to influence product development, replying to customer complaints, and asking websites to withdraw incorrect information. In the present scenario, corporate reputation management has become an important factor of consideration. It is obvious that more number of potential customers will come across the product on the internet with the advent of smartphones and tablets. This creates the need to emphasize on how your brand is presented online. Reputation management is extremely important in building a brand. The company with positive online reviews is expected to thrive well in market while that with the negative public perceptions will experience a decline in customers and sales. Most fortune 500 brand companies are investing huge amounts on reputation management endeavors, which explains its importance of in maintaining the brand value of company. Online corporate reputation management is becoming easier and easier day by day with the increasing access to internet. You just need to monitor your website, social media such as Facebook, Twitter, Google+, etc. Everything else will be handled by online apps. You can improve your online reputation by presenting the things you want them to be presented, interacting with potential customers, and understanding what others are saying about your product or service. Reputation Management on your WebsiteWhenever any user visits your website, they forms an immediate opinion about your brand based on what they see; rather how your website appears. Hence, it is important to present your website in the way you want it to be. If you want it to be more professional, the website image should be more professional, and so on. Also, the website should be informative about what you are offering to the customers and easy to navigate. It is equally important to have the space for visitors to leave their feedbacks. This serves several purposes:It helps in understanding what people think about your brandIt allows visitors to feel more involved by providing their valuable opinionsIt helps other customers in knowing what they can expect from youKnowing what people think about your brand helps in knowing what you are doing right and how you can keep it up. Also, allowing visitors believe that their opinion matters helps in establishing your corporate reputation as a company.  <br><br>Original Post <a href=http://www.salisonline.org/news/corporate-reputation-management.asp>Corporate Reputation Management</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></description><content:encoded><![CDATA[Reputation management is the practice of determining or influencing the behavior of any business or individual&rsquo;s reputation. Originally considered as a public relation term, it was later viewed as an issue of the search results due to the advancements in computing, social media and internet. It deals with the major areas such as astroturfing review sites, use of gamey SEO tactics for influencing results, and censoring negative complaints. It also includes other forms of management such as making use of online feedbacks to influence product development, replying to customer complaints, and asking websites to withdraw incorrect information. In the present scenario, corporate reputation management has become an important factor of consideration. It is obvious that more number of potential customers will come across the product on the internet with the advent of smartphones and tablets. This creates the need to emphasize on how your brand is presented online. Reputation management is extremely important in building a brand. The company with positive online reviews is expected to thrive well in market while that with the negative public perceptions will experience a decline in customers and sales. Most fortune 500 brand companies are investing huge amounts on reputation management endeavors, which explains its importance of in maintaining the brand value of company. Online corporate reputation management is becoming easier and easier day by day with the increasing access to internet. You just need to monitor your website, social media such as Facebook, Twitter, Google+, etc. Everything else will be handled by online apps. You can improve your online reputation by presenting the things you want them to be presented, interacting with potential customers, and understanding what others are saying about your product or service. Reputation Management on your WebsiteWhenever any user visits your website, they forms an immediate opinion about your brand based on what they see; rather how your website appears. Hence, it is important to present your website in the way you want it to be. If you want it to be more professional, the website image should be more professional, and so on. Also, the website should be informative about what you are offering to the customers and easy to navigate. It is equally important to have the space for visitors to leave their feedbacks. This serves several purposes:It helps in understanding what people think about your brandIt allows visitors to feel more involved by providing their valuable opinionsIt helps other customers in knowing what they can expect from youKnowing what people think about your brand helps in knowing what you are doing right and how you can keep it up. Also, allowing visitors believe that their opinion matters helps in establishing your corporate reputation as a company.  <br><br>Original Post <a href=http://www.salisonline.org/news/corporate-reputation-management.asp>Corporate Reputation Management</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></content:encoded><wfw:commentRss>http://www.salisonline.org/news/corporate-reputation-management.asp/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>AT&amp;T Welcomes USD 49.99 LG Escape to its 4G LTE Family</title><link>http://www.salisonline.org/news/atandt-welcomes-usd-4999-lg-escape-to-its-4g-lte-family.asp</link><comments>http://www.salisonline.org/news/atandt-welcomes-usd-4999-lg-escape-to-its-4g-lte-family.asp#comments</comments><pubDate>Wed, 31 Dec 1969 18:00:00 -0600</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.salisonline.org/news/atandt-welcomes-usd-4999-lg-escape-to-its-4g-lte-family.asp</guid><description><![CDATA[On 16 Sep 2012, AT&amp;T will add the LG Escape to its 4G LTE family. Senior Vice President of AT&amp;T Mobility, Jeffy Bradley said that the LG Escape runs on Android Ice Cream Sandwich. The Company will sell this device for USD 49.99 for a contract of two years. AT&amp;T has publicized this device for low budget customers who are looking to enter the Smart Phone market. Consumers looking for inconceivable value will immediately choose the Escape.&nbsp;

The device consists of a 5-megapixel auto adjustable camera with constant shot feature that allows consumers to take continuous snaps for panoramic shots. This will help to grab each memorable moment without missing a second of an impromptu photo with friends.&nbsp;

AT&amp;T said that the feature called &lsquo;time catch shot&rsquo; removes shutter lag by taking numerous snaps before the shutter button is pressed. The LG Escape consists of 4GB inbuilt memory which is further expanded up to 32GB, 4.3 inches qHD IPS display and 1.2 GHz dual-core processor. This device also offers new feature called Skyfire horizon. The Skyfire is a browser toolbar which allows the user access to various social media web pages during surfing through Smart Phones. This feature will allow the user to get quick access to sites like Twitter, Facebook and others. It also allows the user to share URLs and more. The Escape launch comes soon after the company has publicized its shared data plan. <br><br>Original Post <a href=http://www.salisonline.org/news/atandt-welcomes-usd-4999-lg-escape-to-its-4g-lte-family.asp>AT&amp;T Welcomes USD 49.99 LG Escape to its 4G LTE Family</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></description><content:encoded><![CDATA[On 16 Sep 2012, AT&amp;T will add the LG Escape to its 4G LTE family. Senior Vice President of AT&amp;T Mobility, Jeffy Bradley said that the LG Escape runs on Android Ice Cream Sandwich. The Company will sell this device for USD 49.99 for a contract of two years. AT&amp;T has publicized this device for low budget customers who are looking to enter the Smart Phone market. Consumers looking for inconceivable value will immediately choose the Escape.&nbsp;

The device consists of a 5-megapixel auto adjustable camera with constant shot feature that allows consumers to take continuous snaps for panoramic shots. This will help to grab each memorable moment without missing a second of an impromptu photo with friends.&nbsp;

AT&amp;T said that the feature called &lsquo;time catch shot&rsquo; removes shutter lag by taking numerous snaps before the shutter button is pressed. The LG Escape consists of 4GB inbuilt memory which is further expanded up to 32GB, 4.3 inches qHD IPS display and 1.2 GHz dual-core processor. This device also offers new feature called Skyfire horizon. The Skyfire is a browser toolbar which allows the user access to various social media web pages during surfing through Smart Phones. This feature will allow the user to get quick access to sites like Twitter, Facebook and others. It also allows the user to share URLs and more. The Escape launch comes soon after the company has publicized its shared data plan. <br><br>Original Post <a href=http://www.salisonline.org/news/atandt-welcomes-usd-4999-lg-escape-to-its-4g-lte-family.asp>AT&amp;T Welcomes USD 49.99 LG Escape to its 4G LTE Family</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></content:encoded><wfw:commentRss>http://www.salisonline.org/news/atandt-welcomes-usd-4999-lg-escape-to-its-4g-lte-family.asp/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Intertek Group Introduces Polymer Testing Toolbox</title><link>http://www.salisonline.org/news/intertek-group-introduces-polymer-testing-toolbox.asp</link><comments>http://www.salisonline.org/news/intertek-group-introduces-polymer-testing-toolbox.asp#comments</comments><pubDate>Wed, 31 Dec 1969 18:00:00 -0600</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.salisonline.org/news/intertek-group-introduces-polymer-testing-toolbox.asp</guid><description><![CDATA[Intertek Group plc, headquartered in Wilton, UK, has introduced a Medical Device Polymer Testing Toolbox service for clients involved in raw material processing and manufacturing of polymer components for medical devices and their packaging. This toolbox is mainly focused on the application of chemical and physical analysis of medical device polymers. Intertek has developed this core package toolbox to meet the increasing demand of a rapidly growing plastic market and its emerging application in medical industries and tools. This tool is developed by experts and scientists in the field.&nbsp;

The testing toolbox comprises a range of physical testing methods and tools for investigation such as Fourier Transform Infrared Spectroscopy, Electron Microscopy, X-Ray Photoelectron Spectroscopy, Secondary Ion Mass Spectrometry, Rheological, Nuclear Magnetic Resonance Spectrometry, Lubricity and Mechanical property measurements. Mass Spectrometry facilitates a comprehensive understanding of the polymer materials under study.

&ldquo;Scientists today have a wide range of analytical instrumentation to select from to investigate chemical and physical problems with medical device polymers raw materials and finished products. However, it is selection of the most appropriate technique or combination of techniques and how they are applied which is most crucial to understanding the problem and achieving resolution." <br><br>Original Post <a href=http://www.salisonline.org/news/intertek-group-introduces-polymer-testing-toolbox.asp>Intertek Group Introduces Polymer Testing Toolbox</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></description><content:encoded><![CDATA[Intertek Group plc, headquartered in Wilton, UK, has introduced a Medical Device Polymer Testing Toolbox service for clients involved in raw material processing and manufacturing of polymer components for medical devices and their packaging. This toolbox is mainly focused on the application of chemical and physical analysis of medical device polymers. Intertek has developed this core package toolbox to meet the increasing demand of a rapidly growing plastic market and its emerging application in medical industries and tools. This tool is developed by experts and scientists in the field.&nbsp;

The testing toolbox comprises a range of physical testing methods and tools for investigation such as Fourier Transform Infrared Spectroscopy, Electron Microscopy, X-Ray Photoelectron Spectroscopy, Secondary Ion Mass Spectrometry, Rheological, Nuclear Magnetic Resonance Spectrometry, Lubricity and Mechanical property measurements. Mass Spectrometry facilitates a comprehensive understanding of the polymer materials under study.

&ldquo;Scientists today have a wide range of analytical instrumentation to select from to investigate chemical and physical problems with medical device polymers raw materials and finished products. However, it is selection of the most appropriate technique or combination of techniques and how they are applied which is most crucial to understanding the problem and achieving resolution." <br><br>Original Post <a href=http://www.salisonline.org/news/intertek-group-introduces-polymer-testing-toolbox.asp>Intertek Group Introduces Polymer Testing Toolbox</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></content:encoded><wfw:commentRss>http://www.salisonline.org/news/intertek-group-introduces-polymer-testing-toolbox.asp/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Drought Tolerant Seeds for Farmers in Few Months</title><link>http://www.salisonline.org/news/drought-tolerant-seeds-for-farmers-in-few-months.asp</link><comments>http://www.salisonline.org/news/drought-tolerant-seeds-for-farmers-in-few-months.asp#comments</comments><pubDate>Wed, 31 Dec 1969 18:00:00 -0600</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.salisonline.org/news/drought-tolerant-seeds-for-farmers-in-few-months.asp</guid><description><![CDATA[Seed companies have come up with a new invention in seed technology, which will reach farmers in the next few months. The seeds are drought tolerant and susceptible to drought conditions, offering a ray of hope to farmers who suffer from loss due to dry summers and scarce rains. The seeds were displayed at the DuPont Pioneer, Syngenta and Monsanto exhibits early last week at a show in Boone.

The genetic revolution has brought about this innovation of drought tolerance. The seeds offer pest and weed resistance too. This will increase the yields by around 35% to 40%. The new seeds do not completely erase the drought impact but the companies claim that the yield could give some relief to the farmers, thus lowering the loss which they normally bear in the event of drought-like conditions. The seed companies have long been developing drought tolerant corn. Drought tolerant seeds are more complicated. There is no such gene which could be identified that will defeat the drought conditions like it is possible for bugs or weeds.

Doubts had been prevailing about the marketability of drought tolerant corn seeds as they are not really saleable in the areas where there is sufficient rainfall without mechanical irrigation. However, they can be useful at places facing severe droughts. Vern Smith, who farms near West Liberty, said his farm benefited from some strategically aimed rain this summer.&ldquo;My neighbors were estimated at 185 bushels per acre by Pro Farmer, and I think it&rsquo;ll be around that,&rdquo; Smith said. He examined the display for Syngenta&rsquo;s artesian drought-tolerant line and said, &ldquo;I&rsquo;ll be interested in buying some for the next season.&rdquo;
Still the seed companies are not over promising on the concept. They are not making any specific claims on the yields for Droughtguard, but the increase of around 5% to 10% has been observed above the normal yield.

The product has been designed primarily for the Western, and driest part of the corn belt that encompasses the Texas Panhandle and the western halves of Oklahoma, Kansas, Nebraska and the Dakotas. The biotech seed lines cannot be launched without approvals from all major users. The company&rsquo;s manufacturing will have to take all such approvals in the next few months. <br><br>Original Post <a href=http://www.salisonline.org/news/drought-tolerant-seeds-for-farmers-in-few-months.asp>Drought Tolerant Seeds for Farmers in Few Months</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></description><content:encoded><![CDATA[Seed companies have come up with a new invention in seed technology, which will reach farmers in the next few months. The seeds are drought tolerant and susceptible to drought conditions, offering a ray of hope to farmers who suffer from loss due to dry summers and scarce rains. The seeds were displayed at the DuPont Pioneer, Syngenta and Monsanto exhibits early last week at a show in Boone.

The genetic revolution has brought about this innovation of drought tolerance. The seeds offer pest and weed resistance too. This will increase the yields by around 35% to 40%. The new seeds do not completely erase the drought impact but the companies claim that the yield could give some relief to the farmers, thus lowering the loss which they normally bear in the event of drought-like conditions. The seed companies have long been developing drought tolerant corn. Drought tolerant seeds are more complicated. There is no such gene which could be identified that will defeat the drought conditions like it is possible for bugs or weeds.

Doubts had been prevailing about the marketability of drought tolerant corn seeds as they are not really saleable in the areas where there is sufficient rainfall without mechanical irrigation. However, they can be useful at places facing severe droughts. Vern Smith, who farms near West Liberty, said his farm benefited from some strategically aimed rain this summer.&ldquo;My neighbors were estimated at 185 bushels per acre by Pro Farmer, and I think it&rsquo;ll be around that,&rdquo; Smith said. He examined the display for Syngenta&rsquo;s artesian drought-tolerant line and said, &ldquo;I&rsquo;ll be interested in buying some for the next season.&rdquo;
Still the seed companies are not over promising on the concept. They are not making any specific claims on the yields for Droughtguard, but the increase of around 5% to 10% has been observed above the normal yield.

The product has been designed primarily for the Western, and driest part of the corn belt that encompasses the Texas Panhandle and the western halves of Oklahoma, Kansas, Nebraska and the Dakotas. The biotech seed lines cannot be launched without approvals from all major users. The company&rsquo;s manufacturing will have to take all such approvals in the next few months. <br><br>Original Post <a href=http://www.salisonline.org/news/drought-tolerant-seeds-for-farmers-in-few-months.asp>Drought Tolerant Seeds for Farmers in Few Months</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></content:encoded><wfw:commentRss>http://www.salisonline.org/news/drought-tolerant-seeds-for-farmers-in-few-months.asp/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Alphena Pharma Solutions Inc. Acquires Classic Pharmaceuticals LLC</title><link>http://www.salisonline.org/news/alphena-pharma-solutions-inc-acquires-classic-pharmaceuticals-llc.asp</link><comments>http://www.salisonline.org/news/alphena-pharma-solutions-inc-acquires-classic-pharmaceuticals-llc.asp#comments</comments><pubDate>Wed, 31 Dec 1969 18:00:00 -0600</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.salisonline.org/news/alphena-pharma-solutions-inc-acquires-classic-pharmaceuticals-llc.asp</guid><description><![CDATA[Alphena Pharma solutions Inc., a Philadelphia based, leading pharmaceutical and medical packaging provider in the U.S. has acquired Classic Pharmaceuticals LLC, a manufacturer and distributor of blue chip drugs in the U.S. Classic Pharmaceuticals is a huge distributor of over- the-counter, private label pharmaceuticals products in retail stores within the U.S. Their products are distributed and sold in more than 16,000 drug stores nationwide. They also have a wide range of independent pharmacies and other non pharmacy locations to distribute their products. The company&rsquo;s headquarter is in Sherburne, New York.&nbsp;

Classic Pharmaceuticals has recently launched two new products, one a nasal inhaler for cold and flu symptoms and the other a chocolate laxative. Both the products were over-the-counter private label products and were manufactured and packaged in the company&rsquo;s facility in New York. They have distributed both these products throughout the U.S. in major drug stores.

According to Renard Jackson, President and CEO of Alphena Pharma Solutions, this strategic acquisition will be helpful for them to create and maintain a strong customer base with additional private label opportunities. Classic Pharmaceuticals has provided them two very solid products to increase their customer database, expand the company&rsquo;s revenue and enhance their private label business in this division.&nbsp;

The acquisition is expected to help Alphena Pharma Solutions expand their business in dietary supplements, animal health and beauty and medical device markets. This also helps the company to expand globally beyond the U.S. and increase their private label packaging and manufacturing products business. <br><br>Original Post <a href=http://www.salisonline.org/news/alphena-pharma-solutions-inc-acquires-classic-pharmaceuticals-llc.asp>Alphena Pharma Solutions Inc. Acquires Classic Pharmaceuticals LLC</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></description><content:encoded><![CDATA[Alphena Pharma solutions Inc., a Philadelphia based, leading pharmaceutical and medical packaging provider in the U.S. has acquired Classic Pharmaceuticals LLC, a manufacturer and distributor of blue chip drugs in the U.S. Classic Pharmaceuticals is a huge distributor of over- the-counter, private label pharmaceuticals products in retail stores within the U.S. Their products are distributed and sold in more than 16,000 drug stores nationwide. They also have a wide range of independent pharmacies and other non pharmacy locations to distribute their products. The company&rsquo;s headquarter is in Sherburne, New York.&nbsp;

Classic Pharmaceuticals has recently launched two new products, one a nasal inhaler for cold and flu symptoms and the other a chocolate laxative. Both the products were over-the-counter private label products and were manufactured and packaged in the company&rsquo;s facility in New York. They have distributed both these products throughout the U.S. in major drug stores.

According to Renard Jackson, President and CEO of Alphena Pharma Solutions, this strategic acquisition will be helpful for them to create and maintain a strong customer base with additional private label opportunities. Classic Pharmaceuticals has provided them two very solid products to increase their customer database, expand the company&rsquo;s revenue and enhance their private label business in this division.&nbsp;

The acquisition is expected to help Alphena Pharma Solutions expand their business in dietary supplements, animal health and beauty and medical device markets. This also helps the company to expand globally beyond the U.S. and increase their private label packaging and manufacturing products business. <br><br>Original Post <a href=http://www.salisonline.org/news/alphena-pharma-solutions-inc-acquires-classic-pharmaceuticals-llc.asp>Alphena Pharma Solutions Inc. Acquires Classic Pharmaceuticals LLC</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></content:encoded><wfw:commentRss>http://www.salisonline.org/news/alphena-pharma-solutions-inc-acquires-classic-pharmaceuticals-llc.asp/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>VIDA Diagnostics Launches Apollo at 1.2</title><link>http://www.salisonline.org/news/vida-diagnostics-launches-apollo-at-12.asp</link><comments>http://www.salisonline.org/news/vida-diagnostics-launches-apollo-at-12.asp#comments</comments><pubDate>Wed, 31 Dec 1969 18:00:00 -0600</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.salisonline.org/news/vida-diagnostics-launches-apollo-at-12.asp</guid><description><![CDATA[VIDA Diagnostics announced earlier yesterday the release of their commercialization of Apollo&reg; 1.2 at the meeting of the ERS (European Respiratory Society) in Vienna, Austria.&nbsp;

VIDA is a leading manufacturer of imaging analysis software that is utilized for the diagnosis and treatment planning of pulmonary diseases. It is believed by the Company&rsquo;s executives that Apollo&reg; 1.2 will ensure more efficient data and work-flow technology. The new software has a highly interactive procedure planning software. It can be utilized for endobronchial biopsies and also treatment procedures for reduction of lung volume. It is also believed to be the first ever lobar fissure integrity scoring technique which can be utilized for the evaluation of collateral ventilation for treating emphysema patients.

With the introduction of Apollo&reg; 1.2, VIDA has taken a giant leap in the diagnostics software market. Vida Diagnostics excels as a leader in diagnosis and planning of several pulmonary diseases like emphysema, COPD, asthma and lung cancer. VIDA&rsquo;s Apollo is highly capable of diagnosis and treatment assistance of lungs, lobe volumes, airway diameters and parenchymal densities. The outcomes generated are trusted by physicians to be efficient and precise. Apollo has acquired FDA approval and is also CE certified. The analysis methodology of VIDA has been approved in several pharma trials and academia.
Globally, COPD i.e. Chronic Obstructive Pulmonary Disease is believed to be the 3rd major cause of death. It is stated that in the U.S. at least one person dies of COPD every four minutes.

The patient selection procedure is vital in treatment for lung volume reduction. It is also a necessary part in the treatment management of patients suffering with emphysema. The quantitative biomarkers are being integrated using Apollo in clinical routines for taking efficient measures in patient selection and treatment planning. <br><br>Original Post <a href=http://www.salisonline.org/news/vida-diagnostics-launches-apollo-at-12.asp>VIDA Diagnostics Launches Apollo at 1.2</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></description><content:encoded><![CDATA[VIDA Diagnostics announced earlier yesterday the release of their commercialization of Apollo&reg; 1.2 at the meeting of the ERS (European Respiratory Society) in Vienna, Austria.&nbsp;

VIDA is a leading manufacturer of imaging analysis software that is utilized for the diagnosis and treatment planning of pulmonary diseases. It is believed by the Company&rsquo;s executives that Apollo&reg; 1.2 will ensure more efficient data and work-flow technology. The new software has a highly interactive procedure planning software. It can be utilized for endobronchial biopsies and also treatment procedures for reduction of lung volume. It is also believed to be the first ever lobar fissure integrity scoring technique which can be utilized for the evaluation of collateral ventilation for treating emphysema patients.

With the introduction of Apollo&reg; 1.2, VIDA has taken a giant leap in the diagnostics software market. Vida Diagnostics excels as a leader in diagnosis and planning of several pulmonary diseases like emphysema, COPD, asthma and lung cancer. VIDA&rsquo;s Apollo is highly capable of diagnosis and treatment assistance of lungs, lobe volumes, airway diameters and parenchymal densities. The outcomes generated are trusted by physicians to be efficient and precise. Apollo has acquired FDA approval and is also CE certified. The analysis methodology of VIDA has been approved in several pharma trials and academia.
Globally, COPD i.e. Chronic Obstructive Pulmonary Disease is believed to be the 3rd major cause of death. It is stated that in the U.S. at least one person dies of COPD every four minutes.

The patient selection procedure is vital in treatment for lung volume reduction. It is also a necessary part in the treatment management of patients suffering with emphysema. The quantitative biomarkers are being integrated using Apollo in clinical routines for taking efficient measures in patient selection and treatment planning. <br><br>Original Post <a href=http://www.salisonline.org/news/vida-diagnostics-launches-apollo-at-12.asp>VIDA Diagnostics Launches Apollo at 1.2</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></content:encoded><wfw:commentRss>http://www.salisonline.org/news/vida-diagnostics-launches-apollo-at-12.asp/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>India Infoline Finance Ltd all set to focus on Healthcare Finance Business</title><link>http://www.salisonline.org/news/india-infoline-finance-ltd-all-set-to-focus-on-healthcare-finance-business.asp</link><comments>http://www.salisonline.org/news/india-infoline-finance-ltd-all-set-to-focus-on-healthcare-finance-business.asp#comments</comments><pubDate>Wed, 31 Dec 1969 18:00:00 -0600</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.salisonline.org/news/india-infoline-finance-ltd-all-set-to-focus-on-healthcare-finance-business.asp</guid><description><![CDATA[India Infoline Finance Ltd, a subsidiary of India Infoline is eying the financing in health care business for the purpose of growing in the capital market. In the previous fiscal year (FY11) health care financing was Rs 13.9 crore and in the current fiscal year (FY12) health care financing is around Rs 151.56 crore. &nbsp;The company is planning to pay more attention to this niche area in the fiscal year &lsquo;13.

India Infoline provides customized services to their customers in the form of financial solutions to hospitals, nursing homes and doctors to fulfill their funding needs. They also cover financing for medical equipments, brown field projects and refurbished equipments, pathology labs, etc. India Infoline provides finance against the personal guarantee and mortgage of property.

Healthcare industry is the second largest service sector employer in India, and it provides jobs to 4.5 million people. This industry is rapidly growing and for expansion purposes it requires more funding from the public as well.
India Infoline is already active in gold loans, mortgages, capital market financing and with an eye to expand their business they have ventured into the health care business as well. While the current financing is up to only 61 months, India Infoline is providing finance for tenure of 84 months. <br><br>Original Post <a href=http://www.salisonline.org/news/india-infoline-finance-ltd-all-set-to-focus-on-healthcare-finance-business.asp>India Infoline Finance Ltd all set to focus on Healthcare Finance Business</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></description><content:encoded><![CDATA[India Infoline Finance Ltd, a subsidiary of India Infoline is eying the financing in health care business for the purpose of growing in the capital market. In the previous fiscal year (FY11) health care financing was Rs 13.9 crore and in the current fiscal year (FY12) health care financing is around Rs 151.56 crore. &nbsp;The company is planning to pay more attention to this niche area in the fiscal year &lsquo;13.

India Infoline provides customized services to their customers in the form of financial solutions to hospitals, nursing homes and doctors to fulfill their funding needs. They also cover financing for medical equipments, brown field projects and refurbished equipments, pathology labs, etc. India Infoline provides finance against the personal guarantee and mortgage of property.

Healthcare industry is the second largest service sector employer in India, and it provides jobs to 4.5 million people. This industry is rapidly growing and for expansion purposes it requires more funding from the public as well.
India Infoline is already active in gold loans, mortgages, capital market financing and with an eye to expand their business they have ventured into the health care business as well. While the current financing is up to only 61 months, India Infoline is providing finance for tenure of 84 months. <br><br>Original Post <a href=http://www.salisonline.org/news/india-infoline-finance-ltd-all-set-to-focus-on-healthcare-finance-business.asp>India Infoline Finance Ltd all set to focus on Healthcare Finance Business</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></content:encoded><wfw:commentRss>http://www.salisonline.org/news/india-infoline-finance-ltd-all-set-to-focus-on-healthcare-finance-business.asp/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Pharmaceutical Company Valeant Bolsters its Skin Care Products Portfolio, Buys Medicis for USD 2.6 Billion</title><link>http://www.salisonline.org/news/pharmaceutical-company-valeant-bolsters-its-skin-care-products-portfolio-buys-medicis-for-usd-26-billion.asp</link><comments>http://www.salisonline.org/news/pharmaceutical-company-valeant-bolsters-its-skin-care-products-portfolio-buys-medicis-for-usd-26-billion.asp#comments</comments><pubDate>Wed, 31 Dec 1969 18:00:00 -0600</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.salisonline.org/news/pharmaceutical-company-valeant-bolsters-its-skin-care-products-portfolio-buys-medicis-for-usd-26-billion.asp</guid><description><![CDATA[Canadian drug maker, Valeant Pharmaceuticals International, Inc. has continued its trail of mergers and acquisitions, and is on the verge of concluding its 15th acquisition in the current financial year. Valeant in its bid to expand its global presence and product portfolio in the dermatological products segment has agreed to buy Medicis for USD 2.6 billion. These continuous acquisitions have helped Valeant transform into a global company worth multi-billion dollars.

Since 2008, since the current CEO Michael Pearson took over the company&rsquo;s operations, he has focused on these strategic acquisitions of small pharmaceutical companies in an attempt to expand Valeant&rsquo;s portfolio of products and drugs. Mr. Pearson has guided almost 50 such strategic transactions, which have helped the company churn its annual revenue from USD 600 million in 2008 to USD 3.5 billion till date. Mr. Pearson&rsquo;s inclination towards acquisitions is guided by Valeant&rsquo;s bigger competitors&rsquo; focus on billions of investments on research and development to promote and sustain growth.

The deal is seen as Valeant&rsquo;s efforts to bolster its position in the skin care market by expanding its product line for acne and aesthetic skin care products. The move is also aimed to target the Botox market, which is used as a filler to smoothen wrinkles.&nbsp;

Medicis makes a combination of dermatology products with medical use, including acne care and treatment products. The product portfolio of Medicis includes brands such as Ziana, Solodyn, Perlane, Dysport, and other aesthetic products. Disport is a major competitor to Botox in U.S. and Canada.

Medicis Pharmaceutical Corp. is a Scottsdale, Arizona based company, and manufactures pharmaceutical dermatological products. There was a drop in profits in the second quarter, and shares of Medicis have dropped by 5.1% as compared to last year. Shares of Medicis traded for USD 38 last year. <br><br>Original Post <a href=http://www.salisonline.org/news/pharmaceutical-company-valeant-bolsters-its-skin-care-products-portfolio-buys-medicis-for-usd-26-billion.asp>Pharmaceutical Company Valeant Bolsters its Skin Care Products Portfolio, Buys Medicis for USD 2.6 Billion</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></description><content:encoded><![CDATA[Canadian drug maker, Valeant Pharmaceuticals International, Inc. has continued its trail of mergers and acquisitions, and is on the verge of concluding its 15th acquisition in the current financial year. Valeant in its bid to expand its global presence and product portfolio in the dermatological products segment has agreed to buy Medicis for USD 2.6 billion. These continuous acquisitions have helped Valeant transform into a global company worth multi-billion dollars.

Since 2008, since the current CEO Michael Pearson took over the company&rsquo;s operations, he has focused on these strategic acquisitions of small pharmaceutical companies in an attempt to expand Valeant&rsquo;s portfolio of products and drugs. Mr. Pearson has guided almost 50 such strategic transactions, which have helped the company churn its annual revenue from USD 600 million in 2008 to USD 3.5 billion till date. Mr. Pearson&rsquo;s inclination towards acquisitions is guided by Valeant&rsquo;s bigger competitors&rsquo; focus on billions of investments on research and development to promote and sustain growth.

The deal is seen as Valeant&rsquo;s efforts to bolster its position in the skin care market by expanding its product line for acne and aesthetic skin care products. The move is also aimed to target the Botox market, which is used as a filler to smoothen wrinkles.&nbsp;

Medicis makes a combination of dermatology products with medical use, including acne care and treatment products. The product portfolio of Medicis includes brands such as Ziana, Solodyn, Perlane, Dysport, and other aesthetic products. Disport is a major competitor to Botox in U.S. and Canada.

Medicis Pharmaceutical Corp. is a Scottsdale, Arizona based company, and manufactures pharmaceutical dermatological products. There was a drop in profits in the second quarter, and shares of Medicis have dropped by 5.1% as compared to last year. Shares of Medicis traded for USD 38 last year. <br><br>Original Post <a href=http://www.salisonline.org/news/pharmaceutical-company-valeant-bolsters-its-skin-care-products-portfolio-buys-medicis-for-usd-26-billion.asp>Pharmaceutical Company Valeant Bolsters its Skin Care Products Portfolio, Buys Medicis for USD 2.6 Billion</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></content:encoded><wfw:commentRss>http://www.salisonline.org/news/pharmaceutical-company-valeant-bolsters-its-skin-care-products-portfolio-buys-medicis-for-usd-26-billion.asp/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>European Cloud Computing Market In Need Of a Kick Start</title><link>http://www.salisonline.org/news/european-cloud-computing-market-in-need-of-a-kick-start.asp</link><comments>http://www.salisonline.org/news/european-cloud-computing-market-in-need-of-a-kick-start.asp#comments</comments><pubDate>Wed, 31 Dec 1969 18:00:00 -0600</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.salisonline.org/news/european-cloud-computing-market-in-need-of-a-kick-start.asp</guid><description><![CDATA[Although cloud computing is the fastest growing segment globally, it is found that more than 75 per cent of people are not using cloud services. In a survey conducted by nonprofit organization Business Software Alliances (BSA), out of 4,000 respondents only 24 per cent of respondents used cloud applications like online word processing and email. Globally this data is about 34 per cent. Most of the European computer users said that they don&rsquo;t have any idea about cloud computing and about 65 percent of people said that they have not even heard about it.

Cloud computing is the service which integrates with a company&rsquo;s existing infrastructure and allows users to store data on a virtual server. Cloud computing could help businesses to operate more efficiently with reduced cost by integrating with their existing IT resources.

Robert Holleyman, the President of BSA said that cloud computing will help the European economy with its enormous benefits. Adding further, he said that cloud computing will help governments, consumers and business to use software and IT infrastructure more efficiently and cost effectively.&nbsp;

Although, cloud computing has several benefits, most of the European computer users have little understanding about the concept and they are still hesitant to capitalize these opportunities. In UK, 28 per cent and 24 per cent of computer users in Greece have a high level of familiarity of cloud computing; on the other hand in Poland and France it counts for only 9 per cent and 10 per cent respectively. Greece and Romania account for 39% of computer users who use cloud computing which is more than the world and Europe average. Almost 86 per cent of cloud users are using cloud services for their personal use. In Europe only 29 per cent computer users said that they use cloud computing for business purposes whereas 33 per cent of users globally utilize cloud services for business purposes. In Europe, cloud computing applications are commonly used for e-mail, online games and image storage and word processing.

The European Commission is taking the first step towards encouraging the use and growth of cloud computing with a plan to release the cloud computing strategies for the European Union. <br><br>Original Post <a href=http://www.salisonline.org/news/european-cloud-computing-market-in-need-of-a-kick-start.asp>European Cloud Computing Market In Need Of a Kick Start</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></description><content:encoded><![CDATA[Although cloud computing is the fastest growing segment globally, it is found that more than 75 per cent of people are not using cloud services. In a survey conducted by nonprofit organization Business Software Alliances (BSA), out of 4,000 respondents only 24 per cent of respondents used cloud applications like online word processing and email. Globally this data is about 34 per cent. Most of the European computer users said that they don&rsquo;t have any idea about cloud computing and about 65 percent of people said that they have not even heard about it.

Cloud computing is the service which integrates with a company&rsquo;s existing infrastructure and allows users to store data on a virtual server. Cloud computing could help businesses to operate more efficiently with reduced cost by integrating with their existing IT resources.

Robert Holleyman, the President of BSA said that cloud computing will help the European economy with its enormous benefits. Adding further, he said that cloud computing will help governments, consumers and business to use software and IT infrastructure more efficiently and cost effectively.&nbsp;

Although, cloud computing has several benefits, most of the European computer users have little understanding about the concept and they are still hesitant to capitalize these opportunities. In UK, 28 per cent and 24 per cent of computer users in Greece have a high level of familiarity of cloud computing; on the other hand in Poland and France it counts for only 9 per cent and 10 per cent respectively. Greece and Romania account for 39% of computer users who use cloud computing which is more than the world and Europe average. Almost 86 per cent of cloud users are using cloud services for their personal use. In Europe only 29 per cent computer users said that they use cloud computing for business purposes whereas 33 per cent of users globally utilize cloud services for business purposes. In Europe, cloud computing applications are commonly used for e-mail, online games and image storage and word processing.

The European Commission is taking the first step towards encouraging the use and growth of cloud computing with a plan to release the cloud computing strategies for the European Union. <br><br>Original Post <a href=http://www.salisonline.org/news/european-cloud-computing-market-in-need-of-a-kick-start.asp>European Cloud Computing Market In Need Of a Kick Start</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></content:encoded><wfw:commentRss>http://www.salisonline.org/news/european-cloud-computing-market-in-need-of-a-kick-start.asp/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Taiwan Will Overtake South Korea and Singapore in Biotechnology</title><link>http://www.salisonline.org/news/taiwan-will-overtake-south-korea-and-singapore-in-biotechnology.asp</link><comments>http://www.salisonline.org/news/taiwan-will-overtake-south-korea-and-singapore-in-biotechnology.asp#comments</comments><pubDate>Wed, 31 Dec 1969 18:00:00 -0600</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.salisonline.org/news/taiwan-will-overtake-south-korea-and-singapore-in-biotechnology.asp</guid><description><![CDATA[The legislative speaker Wang Jin-Pyng revealed that eight new drugs are being developed in Taiwan which will get approval from the U.S. Food and Drug Administration in a couple of years. This will help Taiwan to overtake South Korea and Singapore in this field. Last month, Savient Pharmaceuticals was among the performers in the industry with a rise of +109.56%. Another positive stock in the industry, Sarepta Therapeutics Inc (NASDAQ:SRPT), had an YTD performance up +251.96% and moved up +80.80% in July. Its price, as of the latest close, was up 427.23% compared with the 52 week low.

Sharing the conclusions of a forum held in June on biotechnology, Wang said that Taiwan has a leading edge in biotechnology, having introduced ten new drugs presently undergoing clinical trials. Though the country is facing economic problems, its biotechnology sector is advancing and contributing to the country over the past decade. The biotechnology sector will be provided with more sponsorship over the coming years and this will see a more flexible national health insurance reimbursement system.

The government at the same time will look after the industry promotions, adjusting prices and allocating budgets within a year&rsquo;s time span. Around ten policies involving structural changes to the biotechnological sector will be enforced within three years. The biotech institute at Taiwan recently sent delegates to China to promote exchanges on clinical trials of drugs for certain common diseases. This will boost the medical and health cooperation between the two nations. <br><br>Original Post <a href=http://www.salisonline.org/news/taiwan-will-overtake-south-korea-and-singapore-in-biotechnology.asp>Taiwan Will Overtake South Korea and Singapore in Biotechnology</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></description><content:encoded><![CDATA[The legislative speaker Wang Jin-Pyng revealed that eight new drugs are being developed in Taiwan which will get approval from the U.S. Food and Drug Administration in a couple of years. This will help Taiwan to overtake South Korea and Singapore in this field. Last month, Savient Pharmaceuticals was among the performers in the industry with a rise of +109.56%. Another positive stock in the industry, Sarepta Therapeutics Inc (NASDAQ:SRPT), had an YTD performance up +251.96% and moved up +80.80% in July. Its price, as of the latest close, was up 427.23% compared with the 52 week low.

Sharing the conclusions of a forum held in June on biotechnology, Wang said that Taiwan has a leading edge in biotechnology, having introduced ten new drugs presently undergoing clinical trials. Though the country is facing economic problems, its biotechnology sector is advancing and contributing to the country over the past decade. The biotechnology sector will be provided with more sponsorship over the coming years and this will see a more flexible national health insurance reimbursement system.

The government at the same time will look after the industry promotions, adjusting prices and allocating budgets within a year&rsquo;s time span. Around ten policies involving structural changes to the biotechnological sector will be enforced within three years. The biotech institute at Taiwan recently sent delegates to China to promote exchanges on clinical trials of drugs for certain common diseases. This will boost the medical and health cooperation between the two nations. <br><br>Original Post <a href=http://www.salisonline.org/news/taiwan-will-overtake-south-korea-and-singapore-in-biotechnology.asp>Taiwan Will Overtake South Korea and Singapore in Biotechnology</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></content:encoded><wfw:commentRss>http://www.salisonline.org/news/taiwan-will-overtake-south-korea-and-singapore-in-biotechnology.asp/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Puritan Diagnostics Announces its U.S. and Canadian Patents for HydraFlock</title><link>http://www.salisonline.org/news/puritan-diagnostics-announces-its-us-and-canadian-patents-for-hydraflock.asp</link><comments>http://www.salisonline.org/news/puritan-diagnostics-announces-its-us-and-canadian-patents-for-hydraflock.asp#comments</comments><pubDate>Wed, 31 Dec 1969 18:00:00 -0600</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.salisonline.org/news/puritan-diagnostics-announces-its-us-and-canadian-patents-for-hydraflock.asp</guid><description><![CDATA[Puritan Diagnostics LLC of Puritan Medical Products Co. LLC has announced yesterday that they have acquired a Canadian patent and shall be receiving a U.S. patent for its HydraFlock&reg; swab. The examination of this patent has already been conducted. HydraFlock&reg; swab is a unique combination of fibers and a distinct microstructure that facilitates the construction of high quality sample collection with high sensitivity and rapid elution. Patents for this product are pending in several nations worldwide.

The Company is excited about the acquisition of these patents for HydraFlock&reg; swabs. The executives believe that this product is highly innovative and its recognition throughout the world will help in making Puritan&rsquo;s mark on the world.

On the same occasion Puritan also announced that its Liquid Amies System received clearance from the FDA (Food and Drug Administration). The System includes HydraFlock&reg; swab and is already on sale in Europe. It is now available in the United States in combination with the Company&rsquo;s UTM-RT Transport System. Such systems are a very important step in the process of diagnosing both viral and bacterial infections. This transport system facilitates collection and transportation of excellent pre-analytical specimen. It also accommodates both the conventional liquid specimen method of processing and also the automation method. It also includes gram staining and culturing.

Puritan Diagnostics is the largest manufacturer of single use diagnostics and medical products in North America. Its manufacturing unit is located in Guilford, Maine. It includes manufacturing of custom media and has a capability of meeting huge range of customer needs. The Company conducts its R&amp;D, testing, releases and approvals in-house. Puritan is also well commended for its conformation to the quality regulations of the U.S. government.

With this patent acquisition, it is expected that the overall exposure of Puritan shall grow and the Company will successfully be able to enhance its visibility in the global market. <br><br>Original Post <a href=http://www.salisonline.org/news/puritan-diagnostics-announces-its-us-and-canadian-patents-for-hydraflock.asp>Puritan Diagnostics Announces its U.S. and Canadian Patents for HydraFlock</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></description><content:encoded><![CDATA[Puritan Diagnostics LLC of Puritan Medical Products Co. LLC has announced yesterday that they have acquired a Canadian patent and shall be receiving a U.S. patent for its HydraFlock&reg; swab. The examination of this patent has already been conducted. HydraFlock&reg; swab is a unique combination of fibers and a distinct microstructure that facilitates the construction of high quality sample collection with high sensitivity and rapid elution. Patents for this product are pending in several nations worldwide.

The Company is excited about the acquisition of these patents for HydraFlock&reg; swabs. The executives believe that this product is highly innovative and its recognition throughout the world will help in making Puritan&rsquo;s mark on the world.

On the same occasion Puritan also announced that its Liquid Amies System received clearance from the FDA (Food and Drug Administration). The System includes HydraFlock&reg; swab and is already on sale in Europe. It is now available in the United States in combination with the Company&rsquo;s UTM-RT Transport System. Such systems are a very important step in the process of diagnosing both viral and bacterial infections. This transport system facilitates collection and transportation of excellent pre-analytical specimen. It also accommodates both the conventional liquid specimen method of processing and also the automation method. It also includes gram staining and culturing.

Puritan Diagnostics is the largest manufacturer of single use diagnostics and medical products in North America. Its manufacturing unit is located in Guilford, Maine. It includes manufacturing of custom media and has a capability of meeting huge range of customer needs. The Company conducts its R&amp;D, testing, releases and approvals in-house. Puritan is also well commended for its conformation to the quality regulations of the U.S. government.

With this patent acquisition, it is expected that the overall exposure of Puritan shall grow and the Company will successfully be able to enhance its visibility in the global market. <br><br>Original Post <a href=http://www.salisonline.org/news/puritan-diagnostics-announces-its-us-and-canadian-patents-for-hydraflock.asp>Puritan Diagnostics Announces its U.S. and Canadian Patents for HydraFlock</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></content:encoded><wfw:commentRss>http://www.salisonline.org/news/puritan-diagnostics-announces-its-us-and-canadian-patents-for-hydraflock.asp/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>NextGen Healthcare Collaborates with Nipro Diagnostics to Heighten Diabetes Management</title><link>http://www.salisonline.org/news/nextgen-healthcare-collaborates-with-nipro-diagnostics-to-heighten-diabetes-management.asp</link><comments>http://www.salisonline.org/news/nextgen-healthcare-collaborates-with-nipro-diagnostics-to-heighten-diabetes-management.asp#comments</comments><pubDate>Wed, 31 Dec 1969 18:00:00 -0600</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.salisonline.org/news/nextgen-healthcare-collaborates-with-nipro-diagnostics-to-heighten-diabetes-management.asp</guid><description><![CDATA[NextGen Healthcare Information Systems, LLC has announced that it has entered into collaboration with Nipro Diagnostics Inc., thus integrating the latter&rsquo;s blood glucose monitoring system called Trueresult under the gambit of NextGen Ambulatory EHR. NextGen Healthcare Information Systems, LLC is a fully own subsidiary of Quality Systems, Inc. Nipro Diagnostics is a major manufacturer of diabetes management devices and products. Several blood glucose monitoring systems have been launched by Nipro under the co-brand TRUE. Its products have been always acclaimed for its high quality and efficiency.

The instant outcome of this agreement is that the users of NextGen Ambulatory HER shall get an instant access to the data points of patients who use the TRUEresult glucose monitoring system. The physicians&rsquo; efficiency shall increase since they would be able to directly perform tests entry into the patient&rsquo;s database thus eliminating the requirement of manual entry. Thus the entire process shall become seamless, efficient, precise and time saving.

The Nipro Diagnostic Blood Glucose interface works in such a way that it acquires the test readings from the TRUEresult and deposits them into NextGen Ambulatory HER. Further it allows the patients and the physicians to conveniently monitor the information thus captured. The new NextGen Nipro Glucose Meter Interface shall enable the downloading of the blood glucose test readings from Nipro TRUEresult into NextGen&rsquo;s HER automatically for further analysis by the respective physician.

Nipro Diagnostics believes that this partnership shall be highly beneficial for the medical practitioners, increasing their efficiency and ease in diagnostics and thus the product shall be a rage in the diagnostics arena. And ultimately the patients shall also benefit from the above system owing to efficient physician feedback and thus improving the former&rsquo;s diabetes management.

The above partnership shall also increase the importance of home monitoring. Seamless integration of test data will provide the physicians with tools for better management of healthcare and thus improve the overall health without furthermore intervention
. <br><br>Original Post <a href=http://www.salisonline.org/news/nextgen-healthcare-collaborates-with-nipro-diagnostics-to-heighten-diabetes-management.asp>NextGen Healthcare Collaborates with Nipro Diagnostics to Heighten Diabetes Management</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></description><content:encoded><![CDATA[NextGen Healthcare Information Systems, LLC has announced that it has entered into collaboration with Nipro Diagnostics Inc., thus integrating the latter&rsquo;s blood glucose monitoring system called Trueresult under the gambit of NextGen Ambulatory EHR. NextGen Healthcare Information Systems, LLC is a fully own subsidiary of Quality Systems, Inc. Nipro Diagnostics is a major manufacturer of diabetes management devices and products. Several blood glucose monitoring systems have been launched by Nipro under the co-brand TRUE. Its products have been always acclaimed for its high quality and efficiency.

The instant outcome of this agreement is that the users of NextGen Ambulatory HER shall get an instant access to the data points of patients who use the TRUEresult glucose monitoring system. The physicians&rsquo; efficiency shall increase since they would be able to directly perform tests entry into the patient&rsquo;s database thus eliminating the requirement of manual entry. Thus the entire process shall become seamless, efficient, precise and time saving.

The Nipro Diagnostic Blood Glucose interface works in such a way that it acquires the test readings from the TRUEresult and deposits them into NextGen Ambulatory HER. Further it allows the patients and the physicians to conveniently monitor the information thus captured. The new NextGen Nipro Glucose Meter Interface shall enable the downloading of the blood glucose test readings from Nipro TRUEresult into NextGen&rsquo;s HER automatically for further analysis by the respective physician.

Nipro Diagnostics believes that this partnership shall be highly beneficial for the medical practitioners, increasing their efficiency and ease in diagnostics and thus the product shall be a rage in the diagnostics arena. And ultimately the patients shall also benefit from the above system owing to efficient physician feedback and thus improving the former&rsquo;s diabetes management.

The above partnership shall also increase the importance of home monitoring. Seamless integration of test data will provide the physicians with tools for better management of healthcare and thus improve the overall health without furthermore intervention
. <br><br>Original Post <a href=http://www.salisonline.org/news/nextgen-healthcare-collaborates-with-nipro-diagnostics-to-heighten-diabetes-management.asp>NextGen Healthcare Collaborates with Nipro Diagnostics to Heighten Diabetes Management</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></content:encoded><wfw:commentRss>http://www.salisonline.org/news/nextgen-healthcare-collaborates-with-nipro-diagnostics-to-heighten-diabetes-management.asp/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Hospira Makes Strategic Move to Acquires Orchid Chemical’s API and R&amp;D Facility</title><link>http://www.salisonline.org/news/hospira-makes-strategic-move-to-acquires-orchid-chemicals-api-and-randd-facility.asp</link><comments>http://www.salisonline.org/news/hospira-makes-strategic-move-to-acquires-orchid-chemicals-api-and-randd-facility.asp#comments</comments><pubDate>Wed, 31 Dec 1969 18:00:00 -0600</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.salisonline.org/news/hospira-makes-strategic-move-to-acquires-orchid-chemicals-api-and-randd-facility.asp</guid><description><![CDATA[Hospira, Inc. a leading U.S. Drug manufacturer, as part of its long term business strategies and committed efforts in the field of antibiotics, has signed a BTA (Business Transfer Agreement) with Orchid Chemicals and Pharmaceuticals Ltd. (OCPL). As part of the agreement, subject to its final approval from regulatory authorities, Orchid&rsquo;s shareholders, and legal clearance, Hospira would acquire API (Active pharmaceutical ingredient) production facility from OCPL along with its associated research and development facility. The deal is valued at USD 200 million, and is seen as a move by Hospira to ascertain its cost competitiveness and continuous supply of ingredients for other drugs.

The BTA includes transfer of Penicillin and Penem API business, and sale of API facility at Aurangabad along with associated R&amp;D facility at Chennai. Earlier in 2009, Hospira had also acquired injectables business of OCPL Chennai for USD 400 million. The acquisition decision by Hospira is also favored towards OCPL due to OCPL&rsquo;s FDA approval and state-of-art facilities. OCPL&rsquo;s API business is highly recognized in the industry and has gained reputation as a high quality and low cost product manufacturer.

The business sold under BTA agreement currently accounts for approximately 23% of total revenue generated through sales by OCPL for the financial year 2010 &ndash; 2011. It includes entire portfolio of penicillin and related products, including those in pipeline as well. The deal if successful would include transfer of 830 employees to Hospira, who are currently working on related projects.

This move will help Hospira to vertically integrate its operations. The transaction is expected to close by the end of third quarter this year if all clearances are smooth. It would help OCPL to maintain a healthy debt profile. However, with acquisition of Aurangabad facility, some of the non API and non-penicillin based products manufactured at the facility would also be transferred to Hospira, which Hospira has agreed to supply to OCPL as part of a long term agreement spanning for 5 years. <br><br>Original Post <a href=http://www.salisonline.org/news/hospira-makes-strategic-move-to-acquires-orchid-chemicals-api-and-randd-facility.asp>Hospira Makes Strategic Move to Acquires Orchid Chemical’s API and R&amp;D Facility</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></description><content:encoded><![CDATA[Hospira, Inc. a leading U.S. Drug manufacturer, as part of its long term business strategies and committed efforts in the field of antibiotics, has signed a BTA (Business Transfer Agreement) with Orchid Chemicals and Pharmaceuticals Ltd. (OCPL). As part of the agreement, subject to its final approval from regulatory authorities, Orchid&rsquo;s shareholders, and legal clearance, Hospira would acquire API (Active pharmaceutical ingredient) production facility from OCPL along with its associated research and development facility. The deal is valued at USD 200 million, and is seen as a move by Hospira to ascertain its cost competitiveness and continuous supply of ingredients for other drugs.

The BTA includes transfer of Penicillin and Penem API business, and sale of API facility at Aurangabad along with associated R&amp;D facility at Chennai. Earlier in 2009, Hospira had also acquired injectables business of OCPL Chennai for USD 400 million. The acquisition decision by Hospira is also favored towards OCPL due to OCPL&rsquo;s FDA approval and state-of-art facilities. OCPL&rsquo;s API business is highly recognized in the industry and has gained reputation as a high quality and low cost product manufacturer.

The business sold under BTA agreement currently accounts for approximately 23% of total revenue generated through sales by OCPL for the financial year 2010 &ndash; 2011. It includes entire portfolio of penicillin and related products, including those in pipeline as well. The deal if successful would include transfer of 830 employees to Hospira, who are currently working on related projects.

This move will help Hospira to vertically integrate its operations. The transaction is expected to close by the end of third quarter this year if all clearances are smooth. It would help OCPL to maintain a healthy debt profile. However, with acquisition of Aurangabad facility, some of the non API and non-penicillin based products manufactured at the facility would also be transferred to Hospira, which Hospira has agreed to supply to OCPL as part of a long term agreement spanning for 5 years. <br><br>Original Post <a href=http://www.salisonline.org/news/hospira-makes-strategic-move-to-acquires-orchid-chemicals-api-and-randd-facility.asp>Hospira Makes Strategic Move to Acquires Orchid Chemical’s API and R&amp;D Facility</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></content:encoded><wfw:commentRss>http://www.salisonline.org/news/hospira-makes-strategic-move-to-acquires-orchid-chemicals-api-and-randd-facility.asp/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Debra Crew to Head Americas Beverages As Newly Appointed President: PepsiCo</title><link>http://www.salisonline.org/news/debra-crew-to-head-americas-beverages-as-newly-appointed-president-pepsico.asp</link><comments>http://www.salisonline.org/news/debra-crew-to-head-americas-beverages-as-newly-appointed-president-pepsico.asp#comments</comments><pubDate>Wed, 31 Dec 1969 18:00:00 -0600</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.salisonline.org/news/debra-crew-to-head-americas-beverages-as-newly-appointed-president-pepsico.asp</guid><description><![CDATA[PepsiCo has named Debra Crew as President for Americas Beverages. She would be taking charge of the newly expanded role, after the term of Sarah Robb O&rsquo;Hagan comes to an end. The decision has come in wake of Sarah&rsquo;s decision, who was serving as President for sports drink brand Gatorade, to leave the company to explore other opportunities.

Debra Crew in her new role will be reporting to CEO of PepsiCo America Beverages Al Carey, based in Chicago. The transition in role is in line with PepsiCo&rsquo;s strategies to integrate various businesses for enhanced overall efficiency.

In her new assignment, Crew would again be holding multiple responsibilities, involving overseeing PepsiCo&rsquo;s Tropicana and Gatorade business in North America, along with Latin America beverage business.

Crew joined PepsiCo in 2010, and currently heads as President for Company&rsquo;s Western Europe Business and is based in Geneva. She also takes care of additional responsibility for looking after organization&rsquo;s commercial and innovations planning across European markets. By virtue of her multiple discipline exposure, Crew has become a fast growing executive leader and enjoys recognition and appreciation across all cadre&rsquo;s of PepsiCo.

Prior to joining PepsiCo, Crew has worked with Mars Incorporation, holding dual responsibility of a General Manager and Chief Marketing Manager. She has also handled Brand Management and leadership roles working with Kraft Food, gaining exposure to diverse food categories such as desserts, snacks, and food service. She did her MBA from Chicago University. Prior to earning her BA from Denver University, Crew has also served as an Army Officer.

Indra Nooyi, PepsiCo Chairman and CEO feels elated to see Crew taking up new responsibilities and growing as a leader. Her diverse experience has certainly helped PepsiCo drive its success story. The announcements for vacant positions will be made soon in coming weeks, as said by PepsiCo. <br><br>Original Post <a href=http://www.salisonline.org/news/debra-crew-to-head-americas-beverages-as-newly-appointed-president-pepsico.asp>Debra Crew to Head Americas Beverages As Newly Appointed President: PepsiCo</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></description><content:encoded><![CDATA[PepsiCo has named Debra Crew as President for Americas Beverages. She would be taking charge of the newly expanded role, after the term of Sarah Robb O&rsquo;Hagan comes to an end. The decision has come in wake of Sarah&rsquo;s decision, who was serving as President for sports drink brand Gatorade, to leave the company to explore other opportunities.

Debra Crew in her new role will be reporting to CEO of PepsiCo America Beverages Al Carey, based in Chicago. The transition in role is in line with PepsiCo&rsquo;s strategies to integrate various businesses for enhanced overall efficiency.

In her new assignment, Crew would again be holding multiple responsibilities, involving overseeing PepsiCo&rsquo;s Tropicana and Gatorade business in North America, along with Latin America beverage business.

Crew joined PepsiCo in 2010, and currently heads as President for Company&rsquo;s Western Europe Business and is based in Geneva. She also takes care of additional responsibility for looking after organization&rsquo;s commercial and innovations planning across European markets. By virtue of her multiple discipline exposure, Crew has become a fast growing executive leader and enjoys recognition and appreciation across all cadre&rsquo;s of PepsiCo.

Prior to joining PepsiCo, Crew has worked with Mars Incorporation, holding dual responsibility of a General Manager and Chief Marketing Manager. She has also handled Brand Management and leadership roles working with Kraft Food, gaining exposure to diverse food categories such as desserts, snacks, and food service. She did her MBA from Chicago University. Prior to earning her BA from Denver University, Crew has also served as an Army Officer.

Indra Nooyi, PepsiCo Chairman and CEO feels elated to see Crew taking up new responsibilities and growing as a leader. Her diverse experience has certainly helped PepsiCo drive its success story. The announcements for vacant positions will be made soon in coming weeks, as said by PepsiCo. <br><br>Original Post <a href=http://www.salisonline.org/news/debra-crew-to-head-americas-beverages-as-newly-appointed-president-pepsico.asp>Debra Crew to Head Americas Beverages As Newly Appointed President: PepsiCo</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></content:encoded><wfw:commentRss>http://www.salisonline.org/news/debra-crew-to-head-americas-beverages-as-newly-appointed-president-pepsico.asp/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>A 2.8 Million Australian Dollar Deal Signed between Australian University and India’s Department Of Biotechnology</title><link>http://www.salisonline.org/news/a-28-million-australian-dollar-deal-signed-between-australian-university-and-indias-department-of-biotechnology.asp</link><comments>http://www.salisonline.org/news/a-28-million-australian-dollar-deal-signed-between-australian-university-and-indias-department-of-biotechnology.asp#comments</comments><pubDate>Wed, 31 Dec 1969 18:00:00 -0600</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.salisonline.org/news/a-28-million-australian-dollar-deal-signed-between-australian-university-and-indias-department-of-biotechnology.asp</guid><description><![CDATA[A deal worth 2.8 million Australian dollars was signed by an Australian university with India&rsquo;s department of biotechnology. The partnership was done with a motive of eliminating iron deficiency- Anemia in India, which is the major concern and cause of maternal death during childbirth.

The partnership will be led by Quensland University of Technology&rsquo;s centre for Tropical Crop&rsquo;s and Biocommodities, National Agri &ndash; Food Biotechnology Institute. Other partners include Bhabha Atomic Research centre, Tamil Nadu Agriculture University, Indian Horticulture Research and National Research Centre for Banana&rsquo;s.

The research team will be involved in developing new strain of iron rich bananas. The reason is banana is a staple food in India, which is consumed in most parts of the country. The officials said that once the varieties of iron rich bananas are ready they will be available widely and will provide a rich source of iron.

This is a major step ahead in overcoming a major health problem in India where the population is nutrient deficient, said &ldquo;Mrs. Swarup, MD Department of Biotechnology, of Biotechnology Industry Research Assistance Council also known as BIRAC.

The Director of QUT Mr. Dale said that &ldquo;we are honored to enter into an agreement with India as this is the very first technology transfer where Indian government has entered in an agreement with a foreign organization at an international level in the field of biotechnology. BIRAC is contributing AUD 1.4 million for the QOT component and AUD 1.4 million as the cost of the Indian component. This is an ongoing research, which QUT was undertaking to increase the banana contents in Uganda under Gates Foundation.

Mr. Dale said that the project of Indian bananas would take initial four years for development phase and further it will take four to five years to prepare the bananas. Iron deficiency is the major concern in women and children. <br><br>Original Post <a href=http://www.salisonline.org/news/a-28-million-australian-dollar-deal-signed-between-australian-university-and-indias-department-of-biotechnology.asp>A 2.8 Million Australian Dollar Deal Signed between Australian University and India’s Department Of Biotechnology</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></description><content:encoded><![CDATA[A deal worth 2.8 million Australian dollars was signed by an Australian university with India&rsquo;s department of biotechnology. The partnership was done with a motive of eliminating iron deficiency- Anemia in India, which is the major concern and cause of maternal death during childbirth.

The partnership will be led by Quensland University of Technology&rsquo;s centre for Tropical Crop&rsquo;s and Biocommodities, National Agri &ndash; Food Biotechnology Institute. Other partners include Bhabha Atomic Research centre, Tamil Nadu Agriculture University, Indian Horticulture Research and National Research Centre for Banana&rsquo;s.

The research team will be involved in developing new strain of iron rich bananas. The reason is banana is a staple food in India, which is consumed in most parts of the country. The officials said that once the varieties of iron rich bananas are ready they will be available widely and will provide a rich source of iron.

This is a major step ahead in overcoming a major health problem in India where the population is nutrient deficient, said &ldquo;Mrs. Swarup, MD Department of Biotechnology, of Biotechnology Industry Research Assistance Council also known as BIRAC.

The Director of QUT Mr. Dale said that &ldquo;we are honored to enter into an agreement with India as this is the very first technology transfer where Indian government has entered in an agreement with a foreign organization at an international level in the field of biotechnology. BIRAC is contributing AUD 1.4 million for the QOT component and AUD 1.4 million as the cost of the Indian component. This is an ongoing research, which QUT was undertaking to increase the banana contents in Uganda under Gates Foundation.

Mr. Dale said that the project of Indian bananas would take initial four years for development phase and further it will take four to five years to prepare the bananas. Iron deficiency is the major concern in women and children. <br><br>Original Post <a href=http://www.salisonline.org/news/a-28-million-australian-dollar-deal-signed-between-australian-university-and-indias-department-of-biotechnology.asp>A 2.8 Million Australian Dollar Deal Signed between Australian University and India’s Department Of Biotechnology</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></content:encoded><wfw:commentRss>http://www.salisonline.org/news/a-28-million-australian-dollar-deal-signed-between-australian-university-and-indias-department-of-biotechnology.asp/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>The First Clinical Trial of the Local Cancer Drug Approved in United States and New Zealand</title><link>http://www.salisonline.org/news/the-first-clinical-trial-of-the-local-cancer-drug-approved-in-united-states-and-new-zealand.asp</link><comments>http://www.salisonline.org/news/the-first-clinical-trial-of-the-local-cancer-drug-approved-in-united-states-and-new-zealand.asp#comments</comments><pubDate>Wed, 31 Dec 1969 18:00:00 -0600</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.salisonline.org/news/the-first-clinical-trial-of-the-local-cancer-drug-approved-in-united-states-and-new-zealand.asp</guid><description><![CDATA[The Food and Drug Administration (FDA) has granted its approval to an anticancer drug invented in New Zealand named as PR610. They trial has moved forward to be used on humans through its approval from an Investigational New Drug Committee. The first trial will be conducted at Waikato Hospital, Auckland City Hospital and others in United States.

The patients are expected to register themselves from the next week for the clinical trial which will be conducted in small groups and these groups of patients will be treated with different dose levels of PR610 and they will be observed for the changes in blood sugar level, anti &ndash; tumor activity and other side effects if any.

PR610 is designed by Dr Adam Patterson and Dr Jeff Smaill from Maurice centre for Molecular Biodiscovery and Auckland cancer society. It belongs to a new class of hypoxia- activated pro- drugs for the treatment of cancer. Initially the focus will be on the patients with non- small cell lung cancer. The phase I part of the trial will investigate the dose of drugs in patients with solid tumors. PR610 targets the hypoxic regions that are the low oxygen regions in tumors which have shown considerable activity in laboratory. PR610 has particularly out mastered in the anti- drug treatments when compared with other drugs. PR610 shrinks the drug resistant lung cancer with its effect.

This new therapy accounts for a makeable era in the field of personalized medicine in New Zealand. The Director of Maurice Wilkins Centre said,&rdquo; Our scientists and researchers are investing the new drugs in order to fight against the life taking disease- Cancer and the clinical trial is one of its kinds. The credit goes to New Zealand which gives a hope to Cancer patients to fight against it.&rdquo; <br><br>Original Post <a href=http://www.salisonline.org/news/the-first-clinical-trial-of-the-local-cancer-drug-approved-in-united-states-and-new-zealand.asp>The First Clinical Trial of the Local Cancer Drug Approved in United States and New Zealand</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></description><content:encoded><![CDATA[The Food and Drug Administration (FDA) has granted its approval to an anticancer drug invented in New Zealand named as PR610. They trial has moved forward to be used on humans through its approval from an Investigational New Drug Committee. The first trial will be conducted at Waikato Hospital, Auckland City Hospital and others in United States.

The patients are expected to register themselves from the next week for the clinical trial which will be conducted in small groups and these groups of patients will be treated with different dose levels of PR610 and they will be observed for the changes in blood sugar level, anti &ndash; tumor activity and other side effects if any.

PR610 is designed by Dr Adam Patterson and Dr Jeff Smaill from Maurice centre for Molecular Biodiscovery and Auckland cancer society. It belongs to a new class of hypoxia- activated pro- drugs for the treatment of cancer. Initially the focus will be on the patients with non- small cell lung cancer. The phase I part of the trial will investigate the dose of drugs in patients with solid tumors. PR610 targets the hypoxic regions that are the low oxygen regions in tumors which have shown considerable activity in laboratory. PR610 has particularly out mastered in the anti- drug treatments when compared with other drugs. PR610 shrinks the drug resistant lung cancer with its effect.

This new therapy accounts for a makeable era in the field of personalized medicine in New Zealand. The Director of Maurice Wilkins Centre said,&rdquo; Our scientists and researchers are investing the new drugs in order to fight against the life taking disease- Cancer and the clinical trial is one of its kinds. The credit goes to New Zealand which gives a hope to Cancer patients to fight against it.&rdquo; <br><br>Original Post <a href=http://www.salisonline.org/news/the-first-clinical-trial-of-the-local-cancer-drug-approved-in-united-states-and-new-zealand.asp>The First Clinical Trial of the Local Cancer Drug Approved in United States and New Zealand</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></content:encoded><wfw:commentRss>http://www.salisonline.org/news/the-first-clinical-trial-of-the-local-cancer-drug-approved-in-united-states-and-new-zealand.asp/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Wake up Ladies: Its Time to Take Care of Your Health by Yourself</title><link>http://www.salisonline.org/news/wake-up-ladies-its-time-to-take-care-of-your-health-by-yourself.asp</link><comments>http://www.salisonline.org/news/wake-up-ladies-its-time-to-take-care-of-your-health-by-yourself.asp#comments</comments><pubDate>Wed, 31 Dec 1969 18:00:00 -0600</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.salisonline.org/news/wake-up-ladies-its-time-to-take-care-of-your-health-by-yourself.asp</guid><description><![CDATA[U.S. government is providing help to women by providing them free of cost medicines and vaccinations; Government has launched Affordable Care Act by which women will be benefited by these free services. These services include free screening for HIV, pregnancy related problems, reproductive health, screening for diabetes and counseling.&nbsp;

Despite all these facilities women are not finding it very easy to avail them, they feels there are many things in their body which causes dangerous results in terms of health.&nbsp;

Cardiovascular diseases are very common in women. Women should always be ready to take care of her and be aware about the risk factors of disease because awareness can change their life. Women should avoid smoking, drinking and high stress; it does not give any fruitful results to their health.&nbsp;

Women should change their eating habits and always try to have some healthy food while at home or at work. They should include exercise in their daily routine which keeps them stay healthy and fit as well.

Government is seeing their women citizen&rsquo;s health as their first priority; they feel women need more health care services than men. Government is very liberal while making health care policies for women specially. <br><br>Original Post <a href=http://www.salisonline.org/news/wake-up-ladies-its-time-to-take-care-of-your-health-by-yourself.asp>Wake up Ladies: Its Time to Take Care of Your Health by Yourself</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></description><content:encoded><![CDATA[U.S. government is providing help to women by providing them free of cost medicines and vaccinations; Government has launched Affordable Care Act by which women will be benefited by these free services. These services include free screening for HIV, pregnancy related problems, reproductive health, screening for diabetes and counseling.&nbsp;

Despite all these facilities women are not finding it very easy to avail them, they feels there are many things in their body which causes dangerous results in terms of health.&nbsp;

Cardiovascular diseases are very common in women. Women should always be ready to take care of her and be aware about the risk factors of disease because awareness can change their life. Women should avoid smoking, drinking and high stress; it does not give any fruitful results to their health.&nbsp;

Women should change their eating habits and always try to have some healthy food while at home or at work. They should include exercise in their daily routine which keeps them stay healthy and fit as well.

Government is seeing their women citizen&rsquo;s health as their first priority; they feel women need more health care services than men. Government is very liberal while making health care policies for women specially. <br><br>Original Post <a href=http://www.salisonline.org/news/wake-up-ladies-its-time-to-take-care-of-your-health-by-yourself.asp>Wake up Ladies: Its Time to Take Care of Your Health by Yourself</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></content:encoded><wfw:commentRss>http://www.salisonline.org/news/wake-up-ladies-its-time-to-take-care-of-your-health-by-yourself.asp/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Caliber Imaging Launched Two New Skin Diagnosis Equipments</title><link>http://www.salisonline.org/news/caliber-imaging-launched-two-new-skin-diagnosis-equipments.asp</link><comments>http://www.salisonline.org/news/caliber-imaging-launched-two-new-skin-diagnosis-equipments.asp#comments</comments><pubDate>Wed, 31 Dec 1969 18:00:00 -0600</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.salisonline.org/news/caliber-imaging-launched-two-new-skin-diagnosis-equipments.asp</guid><description><![CDATA[Caliber Imaging &amp; Diagnostics, previously known as Lucid. Inc has announced on Tuesday, August 28, the launch of two novel products under it&rsquo;s VivaScope&reg; product range. The VivaScope 3000 and VivaScope 1500 well equipped with creating images of living cells in high-quality. Worldwide, Caliber Imaging &amp; Diagnostics is the leader in Diagnostics and Rapid Cell imaging Technology. The VivaScope imagers range assists the medical practitioners in undertaking efficient and painless biopsies for disease diagnosis.&nbsp;

Both of the above products are well equipped with Caliber Imaging&rsquo;s, cell imaging technology. These devices are able to show precise images which are comparable with standard histology. These new devices are also equipped with touch-enabled monitor and software interface which has further increased the convenience of navigation. The Company has also introduced newly designed electronics and optics for even better speed and image quality.

Caliber Imaging &amp; Diagnostics&rsquo; Rapid Cell ID technique assists medical practitioners in various practices of painless biopsies in dermatology. It is believed by the Company executives that this technology can altogether eliminate the need of any invasive procedures on the skin. Thus it shall reduce pain, increase effectiveness and also save the cost incurred.

The VivaScope 1500 shall assist skin cancer specialists to observe the dimensions of any lesion with highly reliable results. Also, the product can be used for personal care and cosmetic product development. It could be further used for skin disease research as well. The overall mapping area of VivaScope 1500 is said to be approximately 8 mm square.&nbsp;

The other product launched &ndash; VivaScope 3000; is a handheld apparatus. It gives faster imaging and also works as a probe interface. This device shall me instrumental in diagnosis at point of care. Being very light weight, VivaScope 3000 shall assist the physicians to easily monitor skin lesions and do further diagnosis. VivaScope 3000 can be accessorized with exiting VivaScope 1500.

Caliber Imaging &amp; Diagnostics has already begun taking orders for this device and it is believed that it shall start delivery by the end of this year. <br><br>Original Post <a href=http://www.salisonline.org/news/caliber-imaging-launched-two-new-skin-diagnosis-equipments.asp>Caliber Imaging Launched Two New Skin Diagnosis Equipments</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></description><content:encoded><![CDATA[Caliber Imaging &amp; Diagnostics, previously known as Lucid. Inc has announced on Tuesday, August 28, the launch of two novel products under it&rsquo;s VivaScope&reg; product range. The VivaScope 3000 and VivaScope 1500 well equipped with creating images of living cells in high-quality. Worldwide, Caliber Imaging &amp; Diagnostics is the leader in Diagnostics and Rapid Cell imaging Technology. The VivaScope imagers range assists the medical practitioners in undertaking efficient and painless biopsies for disease diagnosis.&nbsp;

Both of the above products are well equipped with Caliber Imaging&rsquo;s, cell imaging technology. These devices are able to show precise images which are comparable with standard histology. These new devices are also equipped with touch-enabled monitor and software interface which has further increased the convenience of navigation. The Company has also introduced newly designed electronics and optics for even better speed and image quality.

Caliber Imaging &amp; Diagnostics&rsquo; Rapid Cell ID technique assists medical practitioners in various practices of painless biopsies in dermatology. It is believed by the Company executives that this technology can altogether eliminate the need of any invasive procedures on the skin. Thus it shall reduce pain, increase effectiveness and also save the cost incurred.

The VivaScope 1500 shall assist skin cancer specialists to observe the dimensions of any lesion with highly reliable results. Also, the product can be used for personal care and cosmetic product development. It could be further used for skin disease research as well. The overall mapping area of VivaScope 1500 is said to be approximately 8 mm square.&nbsp;

The other product launched &ndash; VivaScope 3000; is a handheld apparatus. It gives faster imaging and also works as a probe interface. This device shall me instrumental in diagnosis at point of care. Being very light weight, VivaScope 3000 shall assist the physicians to easily monitor skin lesions and do further diagnosis. VivaScope 3000 can be accessorized with exiting VivaScope 1500.

Caliber Imaging &amp; Diagnostics has already begun taking orders for this device and it is believed that it shall start delivery by the end of this year. <br><br>Original Post <a href=http://www.salisonline.org/news/caliber-imaging-launched-two-new-skin-diagnosis-equipments.asp>Caliber Imaging Launched Two New Skin Diagnosis Equipments</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></content:encoded><wfw:commentRss>http://www.salisonline.org/news/caliber-imaging-launched-two-new-skin-diagnosis-equipments.asp/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Emerging Markets in Health care are sought as the most Developing markets for investments</title><link>http://www.salisonline.org/news/emerging-markets-in-health-care-are-sought-as-the-most-developing-markets-for-investments.asp</link><comments>http://www.salisonline.org/news/emerging-markets-in-health-care-are-sought-as-the-most-developing-markets-for-investments.asp#comments</comments><pubDate>Wed, 31 Dec 1969 18:00:00 -0600</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.salisonline.org/news/emerging-markets-in-health-care-are-sought-as-the-most-developing-markets-for-investments.asp</guid><description><![CDATA[The Boston Company (Asset Management) recently issued a report in which the focus was on emerging markets of Health care Industry. According to this report they predicted that the most developing segments of the industry for investments also focus on the economic benefits of those segments in the emerging markets. These identified segments are health care infrastructure, medical technology, and pharmaceuticals.

It has been noticed that major focus was on healthcare for the middle class only; they had not noticed the other emerging segments in the country. To expand these segments government has started investing in public health care services so that growing population of middle class people can afford the essential and expensive care for themselves and for their families as well.

Other countries like China, Brazil are seeing Health care as a shining market for investment purpose. China is rapidly expanding their health care insurance services and pharmaceutical industry as well. To maintain excellent care like USA, China has to work very hard on the distribution of pharmaceutical and Hospital system.

In Brazil, Healthcare services are not favorable for patients, they face many troubles for instance, while moving to the hospitals they are not even provided spacious waiting rooms, as these waiting rooms are always overcrowded. Hospital staff for medical equipments is not even well trained. These problems are seen as growth opportunities in Brazilian health care industry and it requires more investments from public to have good medical services and better training for staff.

Government investment and middle class investment in the health care industry will certainly reduce the burden of expensive medical services and attracts the more local and multinational companies to invest. Decline in mortality rate, rise in life expectancy and economic development will be the factors for success in these countries. <br><br>Original Post <a href=http://www.salisonline.org/news/emerging-markets-in-health-care-are-sought-as-the-most-developing-markets-for-investments.asp>Emerging Markets in Health care are sought as the most Developing markets for investments</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></description><content:encoded><![CDATA[The Boston Company (Asset Management) recently issued a report in which the focus was on emerging markets of Health care Industry. According to this report they predicted that the most developing segments of the industry for investments also focus on the economic benefits of those segments in the emerging markets. These identified segments are health care infrastructure, medical technology, and pharmaceuticals.

It has been noticed that major focus was on healthcare for the middle class only; they had not noticed the other emerging segments in the country. To expand these segments government has started investing in public health care services so that growing population of middle class people can afford the essential and expensive care for themselves and for their families as well.

Other countries like China, Brazil are seeing Health care as a shining market for investment purpose. China is rapidly expanding their health care insurance services and pharmaceutical industry as well. To maintain excellent care like USA, China has to work very hard on the distribution of pharmaceutical and Hospital system.

In Brazil, Healthcare services are not favorable for patients, they face many troubles for instance, while moving to the hospitals they are not even provided spacious waiting rooms, as these waiting rooms are always overcrowded. Hospital staff for medical equipments is not even well trained. These problems are seen as growth opportunities in Brazilian health care industry and it requires more investments from public to have good medical services and better training for staff.

Government investment and middle class investment in the health care industry will certainly reduce the burden of expensive medical services and attracts the more local and multinational companies to invest. Decline in mortality rate, rise in life expectancy and economic development will be the factors for success in these countries. <br><br>Original Post <a href=http://www.salisonline.org/news/emerging-markets-in-health-care-are-sought-as-the-most-developing-markets-for-investments.asp>Emerging Markets in Health care are sought as the most Developing markets for investments</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></content:encoded><wfw:commentRss>http://www.salisonline.org/news/emerging-markets-in-health-care-are-sought-as-the-most-developing-markets-for-investments.asp/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Monsanto and Alnylam Come Together to Explore Agricultural Biological Technologies</title><link>http://www.salisonline.org/news/monsanto-and-alnylam-come-together-to-explore-agricultural-biological-technologies.asp</link><comments>http://www.salisonline.org/news/monsanto-and-alnylam-come-together-to-explore-agricultural-biological-technologies.asp#comments</comments><pubDate>Wed, 31 Dec 1969 18:00:00 -0600</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.salisonline.org/news/monsanto-and-alnylam-come-together-to-explore-agricultural-biological-technologies.asp</guid><description><![CDATA[Alnylam Pharmaceuticals, Inc. and Monsanto Company confirmed their strategic alliance to develop more advanced biological technologies for agriculture industry. Under the partnership agreement, Monsanto gains access to exclusive global rights to use Alnylam&rsquo;s RNAi based technology platform and intellectual property in agricultural filed along with rights to issue sublicenses. Alnylam in turn will receive USD 29.2 million as direct payment. Alnylam will also have rights to receive royalty payments on products based on Alnylam technology platform and products utilizing Alnylam intellectual property. Alnylam will also receive funding for shared research works and other target payments.

The alliance is for the period of 10 years, and is focused on developing innovative solutions and products in the field of biological technologies to support farmers. The agreement integrates RNAi technology platform of Alnylam with Monsanto&rsquo;s BioDirect technology. The alliance is a strategic move by both companies to leverage opportunities provided by the increased role of biological products and advancements in biological technologies, in the field of agriculture.

Alnylam Pharmaceuticals, Inc. (ALNY &ndash; NASDAQ) is Cambridge based bio-pharmaceutical company working on developing innovative therapeutics in the field of RNAi (RNA interference). Its work is focused on translating RNAi to develop novel class of medicines for genetic diseases. The company has already developed RNAi therapeutics based medicines such as ALN-TTR, ALN-AT3, ALN-TMP and ALN-HPN for treatment of following genetics based diseases ATTR (Transthyretin-mediated amyloidosis), hypercholesterolemia, refractory anemia, and hemoglobinopathies respectively. Alnylam is a global leader in the field of RNAi technologies and has extensive research and development facilities. Leveraging its market leadership, it has formed alliances with many global companies such as Novartis, Takeda, Cubist, and many more. It even has co-founded Regulus Therapeutics Inc. in collaboration with Isis.

Monsanto Company (MON &ndash; NYSE) based in St. Louis is a global provider of biological technology based solutions and products which help small or large scale farmers to enhance their farm&rsquo;s productivity and overall quality of the food. <br><br>Original Post <a href=http://www.salisonline.org/news/monsanto-and-alnylam-come-together-to-explore-agricultural-biological-technologies.asp>Monsanto and Alnylam Come Together to Explore Agricultural Biological Technologies</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></description><content:encoded><![CDATA[Alnylam Pharmaceuticals, Inc. and Monsanto Company confirmed their strategic alliance to develop more advanced biological technologies for agriculture industry. Under the partnership agreement, Monsanto gains access to exclusive global rights to use Alnylam&rsquo;s RNAi based technology platform and intellectual property in agricultural filed along with rights to issue sublicenses. Alnylam in turn will receive USD 29.2 million as direct payment. Alnylam will also have rights to receive royalty payments on products based on Alnylam technology platform and products utilizing Alnylam intellectual property. Alnylam will also receive funding for shared research works and other target payments.

The alliance is for the period of 10 years, and is focused on developing innovative solutions and products in the field of biological technologies to support farmers. The agreement integrates RNAi technology platform of Alnylam with Monsanto&rsquo;s BioDirect technology. The alliance is a strategic move by both companies to leverage opportunities provided by the increased role of biological products and advancements in biological technologies, in the field of agriculture.

Alnylam Pharmaceuticals, Inc. (ALNY &ndash; NASDAQ) is Cambridge based bio-pharmaceutical company working on developing innovative therapeutics in the field of RNAi (RNA interference). Its work is focused on translating RNAi to develop novel class of medicines for genetic diseases. The company has already developed RNAi therapeutics based medicines such as ALN-TTR, ALN-AT3, ALN-TMP and ALN-HPN for treatment of following genetics based diseases ATTR (Transthyretin-mediated amyloidosis), hypercholesterolemia, refractory anemia, and hemoglobinopathies respectively. Alnylam is a global leader in the field of RNAi technologies and has extensive research and development facilities. Leveraging its market leadership, it has formed alliances with many global companies such as Novartis, Takeda, Cubist, and many more. It even has co-founded Regulus Therapeutics Inc. in collaboration with Isis.

Monsanto Company (MON &ndash; NYSE) based in St. Louis is a global provider of biological technology based solutions and products which help small or large scale farmers to enhance their farm&rsquo;s productivity and overall quality of the food. <br><br>Original Post <a href=http://www.salisonline.org/news/monsanto-and-alnylam-come-together-to-explore-agricultural-biological-technologies.asp>Monsanto and Alnylam Come Together to Explore Agricultural Biological Technologies</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></content:encoded><wfw:commentRss>http://www.salisonline.org/news/monsanto-and-alnylam-come-together-to-explore-agricultural-biological-technologies.asp/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Researchers Achieved Breakthrough in Monitoring Synthetic Tissues</title><link>http://www.salisonline.org/news/researchers-achieved-breakthrough-in-monitoring-synthetic-tissues.asp</link><comments>http://www.salisonline.org/news/researchers-achieved-breakthrough-in-monitoring-synthetic-tissues.asp#comments</comments><pubDate>Wed, 31 Dec 1969 18:00:00 -0600</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.salisonline.org/news/researchers-achieved-breakthrough-in-monitoring-synthetic-tissues.asp</guid><description><![CDATA[The Massachusetts Institute of Technology and Harvard have achieved a breakthrough in combining tissue engineering and electronics technology. The researchers have developed a method for creating tissue scaffolds of silicon nanowire that shall contain nanoscale electrodes which shall monitor cellular functions within the living tissues. These scaffolds are 3D, porous and biocompatible in nature. They can be made in any desired shape and then planted in the desired body tissue. The structure of these scaffolds shall be infused with field-effect transistors i.e. FET detectors. These detectors shall monitor any fluctuation in the&nbsp;
physiochemical properties of the tissue thus growing through the implanted scaffold.

These scaffolds can be utilized to overview the electrical responses of the tissues of neural and cardiac cells. They can also be used to view pH changes in the blood vessels that are constructed from smooth muscle cells.

The Harvard and MIT researchers have claimed that his innovative combination of electronics and tissue engineering do not affect the inherent viability and functionality of the cells. They further claim that this technology shall have numerous potential applications in both in vitro and in vivo. Primarily this system shall be used to monitor the tissue responsiveness of the drug candidates on administration of test drugs.

The above research results have been published in Nature Materials, titled &ldquo;Macroporous nanowire nanoelectronic scaffolds for synthetic tissues.&rdquo; &nbsp;The older attempt to create tissue systems that can study physiochemical changes and cellular activity were only developed on 2D layouts. However; this new technology is 3D enabled and have a potential to monitor the physiochemical responsiveness, pH levels, oxygen and several other properties within every part of human body. This technology is named &ldquo;nanoES&rdquo;; it is thus created so that it shall contain polymer precursors, nanowires and of course, the cell tissues. Primary nanowire FET lattice is generated by putting the nanowires in a polymer and further, the polymer is then removed. Finally the nanowire FET are patterned lithographically and integrated into the porous scaffolds and thus the nanoES is constructed.&nbsp;

These scaffolds are then combined with natural or synthetic extracellular matrices. This structure retains its biocompatibility and possesses electrical sensory function thus further paving way to normal tissue culture.

The primary results revealed that the nanoES were efficient to support heart growth in 3D. The sensors in the structure detected and monitored electrical signals in the cultured tissue and also monitored responsiveness to administration of cardiac and neurological stimulator drugs.&nbsp;
Further the researchers used the nanoES in creating blood vessels by using smooth muscle cells and also were successful in measuring pH changes in the blood vessels.

The nanoES is significantly different from 2D multielectrode arrays, implantable microelectrodes and similar other devices in such a way that the sensors in nanoES are nanoscale semiconductors, has a flexible network, is three dimensional and macroporous in nature. <br><br>Original Post <a href=http://www.salisonline.org/news/researchers-achieved-breakthrough-in-monitoring-synthetic-tissues.asp>Researchers Achieved Breakthrough in Monitoring Synthetic Tissues</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></description><content:encoded><![CDATA[The Massachusetts Institute of Technology and Harvard have achieved a breakthrough in combining tissue engineering and electronics technology. The researchers have developed a method for creating tissue scaffolds of silicon nanowire that shall contain nanoscale electrodes which shall monitor cellular functions within the living tissues. These scaffolds are 3D, porous and biocompatible in nature. They can be made in any desired shape and then planted in the desired body tissue. The structure of these scaffolds shall be infused with field-effect transistors i.e. FET detectors. These detectors shall monitor any fluctuation in the&nbsp;
physiochemical properties of the tissue thus growing through the implanted scaffold.

These scaffolds can be utilized to overview the electrical responses of the tissues of neural and cardiac cells. They can also be used to view pH changes in the blood vessels that are constructed from smooth muscle cells.

The Harvard and MIT researchers have claimed that his innovative combination of electronics and tissue engineering do not affect the inherent viability and functionality of the cells. They further claim that this technology shall have numerous potential applications in both in vitro and in vivo. Primarily this system shall be used to monitor the tissue responsiveness of the drug candidates on administration of test drugs.

The above research results have been published in Nature Materials, titled &ldquo;Macroporous nanowire nanoelectronic scaffolds for synthetic tissues.&rdquo; &nbsp;The older attempt to create tissue systems that can study physiochemical changes and cellular activity were only developed on 2D layouts. However; this new technology is 3D enabled and have a potential to monitor the physiochemical responsiveness, pH levels, oxygen and several other properties within every part of human body. This technology is named &ldquo;nanoES&rdquo;; it is thus created so that it shall contain polymer precursors, nanowires and of course, the cell tissues. Primary nanowire FET lattice is generated by putting the nanowires in a polymer and further, the polymer is then removed. Finally the nanowire FET are patterned lithographically and integrated into the porous scaffolds and thus the nanoES is constructed.&nbsp;

These scaffolds are then combined with natural or synthetic extracellular matrices. This structure retains its biocompatibility and possesses electrical sensory function thus further paving way to normal tissue culture.

The primary results revealed that the nanoES were efficient to support heart growth in 3D. The sensors in the structure detected and monitored electrical signals in the cultured tissue and also monitored responsiveness to administration of cardiac and neurological stimulator drugs.&nbsp;
Further the researchers used the nanoES in creating blood vessels by using smooth muscle cells and also were successful in measuring pH changes in the blood vessels.

The nanoES is significantly different from 2D multielectrode arrays, implantable microelectrodes and similar other devices in such a way that the sensors in nanoES are nanoscale semiconductors, has a flexible network, is three dimensional and macroporous in nature. <br><br>Original Post <a href=http://www.salisonline.org/news/researchers-achieved-breakthrough-in-monitoring-synthetic-tissues.asp>Researchers Achieved Breakthrough in Monitoring Synthetic Tissues</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></content:encoded><wfw:commentRss>http://www.salisonline.org/news/researchers-achieved-breakthrough-in-monitoring-synthetic-tissues.asp/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Genzyme to Resubmit Marketing Application as FDA Asks For Revisions</title><link>http://www.salisonline.org/news/genzyme-to-resubmit-marketing-application-as-fda-asks-for-revisions.asp</link><comments>http://www.salisonline.org/news/genzyme-to-resubmit-marketing-application-as-fda-asks-for-revisions.asp#comments</comments><pubDate>Wed, 31 Dec 1969 18:00:00 -0600</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.salisonline.org/news/genzyme-to-resubmit-marketing-application-as-fda-asks-for-revisions.asp</guid><description><![CDATA[U.S. Food and Drugs Administration (FDA), has asked Genzyme, a Sanofi company, to resubmit its marketing application after modifying the data presentation in supplement biologics license application (sBLA) for approval of its new drug Lemtrada.

Genzyme, which is a rare disease division of Sanofi, has been working for the past 30 years on developing pioneering solutions for delivering transformative therapies. The company&rsquo;s focus is on developing life saving medicines to be used as part of transformative therapies for rare diseases and multiple sclerosis.

Its new drug Lemtrada, trade name given for alemtuzumab, is developed as a transformative therapy treatment for multiple sclerosis, a rare and incapacitating disease. However, U.S. FDA has asked the company to file the marketing application again after making recommended changes in the sBLA for presentation of data. The changes have been recommended to enable agency to effectively scrutinize and navigate the application.&nbsp;

The company has quoted that it is working in close collaboration with the agency to follow up on the changes required and resubmit the application at the earliest possible. A similar marketing approval application filed at European Medicines Agency is already under the review process. Company is sure that its application will get U.S. FDA approval soon, as the agency has not asked for any additional information or data, but only to modify the data presentation.

Genzyme has been working on developing MS treatment drug Lemtrada (alemtuzumab) in partnership with Bayer HealthCare. Alemtuzumab helps in reducing the MS activity by rebalancing the T and B Cells population. It is a single clone (monoclonal) antibody which targets only CD52 protein, found excessively on T and B cells, without affecting other immune cells. Thus, it depletes the T and B cells which are responsible for destructive action on inflammatory process in multiple sclerosis.

Genzyme has the global rights for development and commercialization of alemtuzumab, and its use in MS. Bayer HealthCare as part of collaborative agreement, has rights to co-promote the product and share the conditional payment on revenue through sales. <br><br>Original Post <a href=http://www.salisonline.org/news/genzyme-to-resubmit-marketing-application-as-fda-asks-for-revisions.asp>Genzyme to Resubmit Marketing Application as FDA Asks For Revisions</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></description><content:encoded><![CDATA[U.S. Food and Drugs Administration (FDA), has asked Genzyme, a Sanofi company, to resubmit its marketing application after modifying the data presentation in supplement biologics license application (sBLA) for approval of its new drug Lemtrada.

Genzyme, which is a rare disease division of Sanofi, has been working for the past 30 years on developing pioneering solutions for delivering transformative therapies. The company&rsquo;s focus is on developing life saving medicines to be used as part of transformative therapies for rare diseases and multiple sclerosis.

Its new drug Lemtrada, trade name given for alemtuzumab, is developed as a transformative therapy treatment for multiple sclerosis, a rare and incapacitating disease. However, U.S. FDA has asked the company to file the marketing application again after making recommended changes in the sBLA for presentation of data. The changes have been recommended to enable agency to effectively scrutinize and navigate the application.&nbsp;

The company has quoted that it is working in close collaboration with the agency to follow up on the changes required and resubmit the application at the earliest possible. A similar marketing approval application filed at European Medicines Agency is already under the review process. Company is sure that its application will get U.S. FDA approval soon, as the agency has not asked for any additional information or data, but only to modify the data presentation.

Genzyme has been working on developing MS treatment drug Lemtrada (alemtuzumab) in partnership with Bayer HealthCare. Alemtuzumab helps in reducing the MS activity by rebalancing the T and B Cells population. It is a single clone (monoclonal) antibody which targets only CD52 protein, found excessively on T and B cells, without affecting other immune cells. Thus, it depletes the T and B cells which are responsible for destructive action on inflammatory process in multiple sclerosis.

Genzyme has the global rights for development and commercialization of alemtuzumab, and its use in MS. Bayer HealthCare as part of collaborative agreement, has rights to co-promote the product and share the conditional payment on revenue through sales. <br><br>Original Post <a href=http://www.salisonline.org/news/genzyme-to-resubmit-marketing-application-as-fda-asks-for-revisions.asp>Genzyme to Resubmit Marketing Application as FDA Asks For Revisions</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></content:encoded><wfw:commentRss>http://www.salisonline.org/news/genzyme-to-resubmit-marketing-application-as-fda-asks-for-revisions.asp/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>NextGen Healthcare Collaborates with Nipro Diagnostics to Heighten Diabetes Management</title><link>http://www.salisonline.org/news/nextgen-healthcare-collaborates-with-nipro-diagnostics-to-heighten-diabetes-management.asp</link><comments>http://www.salisonline.org/news/nextgen-healthcare-collaborates-with-nipro-diagnostics-to-heighten-diabetes-management.asp#comments</comments><pubDate>Wed, 31 Dec 1969 18:00:00 -0600</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.salisonline.org/news/nextgen-healthcare-collaborates-with-nipro-diagnostics-to-heighten-diabetes-management.asp</guid><description><![CDATA[NextGen Healthcare Information Systems, LLC has announced that it has entered into collaboration with Nipro Diagnostics Inc., thus integrating the latter&rsquo;s blood glucose monitoring system called Trueresult under the gambit of NextGen Ambulatory EHR. NextGen Healthcare Information Systems, LLC is a fully own subsidiary of Quality Systems, Inc. Nipro Diagnostics is a major manufacturer of diabetes management devices and products. Several blood glucose monitoring systems have been launched by Nipro under the co-brand TRUE. Its products have been always acclaimed for its high quality and efficiency.

The instant outcome of this agreement is that the users of NextGen Ambulatory HER shall get an instant access to the data points of patients who use the TRUEresult glucose monitoring system. The physicians&rsquo; efficiency shall increase since they would be able to directly perform tests entry into the patient&rsquo;s database thus eliminating the requirement of manual entry. Thus the entire process shall become seamless, efficient, precise and time saving.

The Nipro Diagnostic Blood Glucose interface works in such a way that it acquires the test readings from the TRUEresult and deposits them into NextGen Ambulatory HER. Further it allows the patients and the physicians to conveniently monitor the information thus captured. The new NextGen Nipro Glucose Meter Interface shall enable the downloading of the blood glucose test readings from Nipro TRUEresult into NextGen&rsquo;s HER automatically for further analysis by the respective physician.

Nipro Diagnostics believes that this partnership shall be highly beneficial for the medical practitioners, increasing their efficiency and ease in diagnostics and thus the product shall be a rage in the diagnostics arena. And ultimately the patients shall also benefit from the above system owing to efficient physician feedback and thus improving the former&rsquo;s diabetes management.

The above partnership shall also increase the importance of home monitoring. Seamless integration of test data will provide the physicians with tools for better management of healthcare and thus improve the overall health without furthermore intervention <br><br>Original Post <a href=http://www.salisonline.org/news/nextgen-healthcare-collaborates-with-nipro-diagnostics-to-heighten-diabetes-management.asp>NextGen Healthcare Collaborates with Nipro Diagnostics to Heighten Diabetes Management</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></description><content:encoded><![CDATA[NextGen Healthcare Information Systems, LLC has announced that it has entered into collaboration with Nipro Diagnostics Inc., thus integrating the latter&rsquo;s blood glucose monitoring system called Trueresult under the gambit of NextGen Ambulatory EHR. NextGen Healthcare Information Systems, LLC is a fully own subsidiary of Quality Systems, Inc. Nipro Diagnostics is a major manufacturer of diabetes management devices and products. Several blood glucose monitoring systems have been launched by Nipro under the co-brand TRUE. Its products have been always acclaimed for its high quality and efficiency.

The instant outcome of this agreement is that the users of NextGen Ambulatory HER shall get an instant access to the data points of patients who use the TRUEresult glucose monitoring system. The physicians&rsquo; efficiency shall increase since they would be able to directly perform tests entry into the patient&rsquo;s database thus eliminating the requirement of manual entry. Thus the entire process shall become seamless, efficient, precise and time saving.

The Nipro Diagnostic Blood Glucose interface works in such a way that it acquires the test readings from the TRUEresult and deposits them into NextGen Ambulatory HER. Further it allows the patients and the physicians to conveniently monitor the information thus captured. The new NextGen Nipro Glucose Meter Interface shall enable the downloading of the blood glucose test readings from Nipro TRUEresult into NextGen&rsquo;s HER automatically for further analysis by the respective physician.

Nipro Diagnostics believes that this partnership shall be highly beneficial for the medical practitioners, increasing their efficiency and ease in diagnostics and thus the product shall be a rage in the diagnostics arena. And ultimately the patients shall also benefit from the above system owing to efficient physician feedback and thus improving the former&rsquo;s diabetes management.

The above partnership shall also increase the importance of home monitoring. Seamless integration of test data will provide the physicians with tools for better management of healthcare and thus improve the overall health without furthermore intervention <br><br>Original Post <a href=http://www.salisonline.org/news/nextgen-healthcare-collaborates-with-nipro-diagnostics-to-heighten-diabetes-management.asp>NextGen Healthcare Collaborates with Nipro Diagnostics to Heighten Diabetes Management</a> source <a href="http://www.salisonline.org">Salisonline</a>]]></content:encoded><wfw:commentRss>http://www.salisonline.org/news/nextgen-healthcare-collaborates-with-nipro-diagnostics-to-heighten-diabetes-management.asp/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item></channel></rss>